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ABSTRACT
Filamentous deposition of microtubule-associated protein tau is a hallmark
for a number of neurodegenerative diseases collectively termed tauopathies.
While tau fibrils are directly linked to the etiology and pathogenesis of these
diseases, fibril morphology and their phenotypic presentation can be quite
disparate. Alternative splicing of tau results in two main isoform groups, fourrepeat (4R) tau and three-repeat (3R), identified by their number of microtubule
binding repeats. Some diseases show deposition of both 4R and 3R isoforms,
while others show preferential deposition of only one type. The conformational
templated growth scheme and trans-synaptic spreading of fibrils is influenced by
fibril conformation. Therefore, conformationally distinct fibrils possessing different
growth properties is one mechanistic explanation for disparate pathology; yet,
molecular level insight on the core structure of these fibrils is lacking. Elucidating
how distinct conformers arise, and how their structural features influence growth
properties is critical to understanding fibril propagation.
The growth properties and the structural impact that physiologically
relevant events including truncation, mutations, and oxidation have on 4R fibrils
were investigated. The ability of full-length 4R fibrils to recruit both 4R and 3R tau
is influenced by residues on its C-terminal end, as a 3R growth barrier was
observed for fibrils formed from C-terminally truncated variants. A 3R growth
ii

barrier was also observed for fibrils with specific disease associated mutations.
Structural investigations highlighted a region of structural disorder in these fibrils
that exhibit 3R growth barriers, in contrast to full-length non-mutated fibrils. Fibrils
formed from an oxidized version of 4R tau, with native cysteines intramolecularly
disulfide bonded, are structurally distinct and exhibit different recruitment
properties from their reduced counterparts. These findings provide mechanistic
insight on how truncations, mutations, and oxidation can dictate fibril
conformation and thus influence propagation.
Techniques for early diagnostic and therapeutic intervention of
tauopathies are limited by their sensitivity of detection. Suppressing tau monomer
self-nucleation is one factor critical to amplification assays used to detect low
fibril concentrations. Increased suppression of self-nucleation was achieved
using mutant tau and modifying assay parameters. These improvements bring
this assay one step closer to detecting ultralow fibril concentrations.
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CHAPTER ONE: INTRODUCTION
1.1

Tauopathies and their impact
Tauopathies are a collection of neurodegenerative diseases characterized

by the filamentous deposition of the microtubule-associated protein tau. Some
share common dementia and/or movement disorder symptoms, but the
pathology of these diseases can be very disparate (1). Tauopathies are a
subclassification of diseases called amyloidoses. Amyloidoses refer to pathology
associated with the deposition of amyloid fibrils, and fall under the broad
category of protein misfolding diseases (2). The most common and well
characterized tauopathy is Alzheimer’s disease (AD). Other diseases
characterized by tau deposition include Chronic Traumatic Encephalopathy
(CTE), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
(CBD), Pick’s disease (PID) and Frontotemporal dementia and parkinsonism
linked to chromosome-17 (FTDP-17) (3, 4). The problem that dementia imposes
is immense, it is a burden not only to those who suffer from it but to caregivers
and the economy as well. The cost of health care for people with AD or other
dementias in just the United States was $277 billion in 2018 (5). If preventative
measures are not developed it is projected that by 2050 the total number of
people with AD dementia, in the United States alone, will be 13.8 million (6).
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Therefore, it is critical that a deeper understanding of the underlying mechanism
of these diseases, like tau fibril formation and propagation, be reached.

1.2

Microtubule associated protein tau
1.2.1 Native function and isoforms of tau
Tau is one protein in the microtubule-associated protein (MAP) family. Tau

protein is primarily expressed in neurons (7) and its normal biological functions
include stimulation of microtubule (MT) assembly and stabilization of MT
structure (8, 9). Proper function of MTs to facilitate axonal transport is vital for
neuronal health, therefore the loss of native tau function is one factor contributing
to neurodegeneration (10). The other main factor is the gain of toxic function from
tau aggregates, deposition of which have been linked to over 20
neurodegenerative diseases (4). In the most common tauopathy, AD, tau was
identified to make up its associated paired helical filaments as early as the late
1980’s (11, 12).
The gene for tau protein is found on chromosome 17 and contains 16
exons. Different isoforms arise due to the alternative splicing of exons 2, 3, and
10 (13). Exon 2 can appear with or without exon 3, but exon 3 never appears
independently of exon 2. This results in a 0, 29, or 58 amino acid insert in the Nterminus (14). The splicing of exon 10 results in the absence of the second of
four semiconserved microtubule binding repeats (MTBRs) in the C-terminal end
of tau. These splicing options give rise to 6 isoforms ranging between 352 to 441
2

amino acids in length; three containing four MTBRs (4R) and three containing
three MTBRs (3R) (Figure 1.1). During development these isoforms are
differentially expressed, signifying that they have particular biological roles. The
3R isoforms provide less MT stabilization and are preferentially present during
fetal stages when greater MT dynamics are needed for development. However,
in the adult human brain all six isoforms are equally expressed (15).

Figure 1.1. Tau isoforms. Six different isoforms of tau arise due to alternative splicing
of exons 2, 3 and 10. Differential splicing of exons 2 and 3 results in the absence or
presence of two N-terminal inserts (striped boxes). The splicing of exon 10 results in the
absence of the second of four microtubule binding repeats (shaded boxes R1-R4).

The N-terminus, referred to as the projection domain, contains inserts that
are acidic followed by a basic proline-rich region. This projection domain is
responsible for interactions with cytoskeletal elements and the neural plasma
membrane along with being involved in signal transduction pathways (16). The
C-terminus contains the 4 or 3 semiconserved repeats. These repeats are
3

extremely important segments of the tau protein because together with the
proline rich region they are responsible for binding to MTs (17). Additionally, in
vitro studies show tau variants that have been truncated to only the repeats are
sufficient to form fibrils (18). This is unsurprising given that proposed and
published fibril structures show that these repeats largely make up the core of
fibrils associated with different tauopathies (19–21). This implies that fibrils
formed from variants containing residues outside the repeats have a large
number of amino acids, particularly in the htau40 isoform, that are not contained
in the structured core. These residues have been referred to as the fuzzy coat
(22). But these residues can still have an impact on fibril growth properties due to
N- or C- terminal regions backfolding to interact with residues in the core (23).

1.2.2

Post-translational modifications and mutations

Tau is prone to a host of post-translational modifications (PTMs) and has
numerous mutations associated with it. Some of these, in combination or
individually, change the growth properties of tau by shifting its aggregation
propensity and/or recruitment properties (24). Some of the post-translational
modifications of tau promote aggregation and include glycation, nitration,
polyamination, sumoylation and ubiquitination (25). Other PTMs that will be
discussed in more detail are the most common, phosphorylation, and the two that
most impact the studies presented herein, truncation and oxidation.

4

1.2.2.1

Phosphorylation

Phosphorylation of tau is one mechanistic way its binding to MTs is
regulated. Since stabilizing MTs along with regulating their assembly are the
main functions of tau, some degree of phosphorylation is necessary (26). A
normal phosphorylation state of tau involves approximately 2-3 moles of
phosphate per mole of tau, but in disease this ratio is much higher, approximately
6-8 moles of phosphate per mole of tau in some AD patients (27). It is the
hyperphosphorylation or mis-phosphorylation of tau monomers that leads to
problems causing their dissociation from MTs and increased propensity to
aggregate (28). Some groups believe the hyperphosphorylation of tau monomers
to be the mechanism by which they dissociate from MTs, then other PTMs
promote the formation of aggregates (25). Monomer refers to any nonaggregated tau variant, this includes full-length, truncated and mutant variants.

1.2.2.2

Truncation

Truncated variants of tau protein have been used for numerous in vitro
studies, and their deposition has been associated with various tauopathies (29).
The development of truncation-dependent conformational antibodies provided
validation that truncated tau variants arise naturally in disease and are not just an
artifact of protease treatment during sample analysis (30). Importantly, some of
these antibodies are not dependent on the phosphorylation state of tau (31–33).
One such antibody, DCII, shows strong immunoreactivity toward variants with
5

either N- or C- terminal truncations, or a combination of both. However, DCII
shows no recognition for endogenous healthy tau or recombinant full-length tau
(31). The first truncated variant to be identified in disease tissue absent of any
protease digestion was a variant truncated at position 391 (numbering scheme
with respect to htau40) (32). Since then, a variety of proteases have been
identified to produce over 50 specific truncated tau fragments. These truncated
variants have been shown to have differential effects in the context of
neurodegenerative diseases (29). The caspase family of proteases has been
shown to cleave tau at a number of different positions (34), and the resulting
cleavage products are linked to different tauopathies such as AD and PSP (35,
36). Caspase activation happens early on in disease progression making it
possible that truncated variants initiate fibril formation (37). Calpain-1 and -2
have been linked to a fragment associated with AD patients containing residues
243-441 (36), and have also been implicated in the creation of fragments that
exclude the MTBRs, yet still have neurotoxic effects (36, 38). Asparagine
endopeptidase has been shown to cleave tau at N255-V256 and N368-K369,
and the resulting 1-368 and 256-368 fragments have exhibited increased
aggregation propensity (39). Other proteases known to be associated with tau
cleavage include cathepsins (40), puromycin-sensitive aminopeptidase (41),
thrombin (42), and a disintegrin and metalloprotease 10 (43). The pathogenicity
of some fragments remain unidentified, along with the origin of other fragments
associated with disease (29). Truncated variants may play a role in initiating
6

aggregation. However, the mechanism by which they contribute to disease is not
thoroughly known, and little has been identified about the impact truncations
have on fibril core structure (44, 45).

1.2.2.3

Oxidation

A loss in redox homeostasis, and therefore increased oxidative stress, is
known to be associated with numerous neurodegenerative diseases including
tauopathies (46). The pathogenesis of diseases like AD are accelerated in many
ways by the disruption of the oxidation-reduction balance. Many effects stem
from this disruption, like the inhibition of proteasomes and/or the accumulation of
reactive oxygen species (ROS), both impact protein aggregation (47).
Considerable characterization has been done concerning the impact that
oxidative processes have on AD with regard to amyloid beta (Aβ), which
constitutes the senile plaques found in AD pathology, particularly oxidative stress
via metal dyshomeostasis (48–50). Chelation of particular endogenous and
exogenous metal ions have even been the subject of potential AD therapeutic
strategies (51–53). While metal ion binding does effect tau aggregation, oxidation
resulting in the formation of disulfide bonds between native cysteines in tau is
also very important. Disulfide bonds in tau have the potential to greatly affect
aggregation properties (54). As such, the aggregation potential of intramolecular
and intermolecular disulfide bonded tau monomers has been the subject of
numerous studies. The formation of intermolecular disulfide bonds, essentially
7

forming tau dimers or higher order species, has been shown to increase
aggregation (55). However, the impact that intramolecular disulfide bonds
(between the two native cysteines in one tau monomer) have on aggregation,
has not been as well studied. There are inconsistencies in the studies that
investigate tau with intramolecular disulfide bonds. For example, some studies
suggest this species does not form fibrils (56), while other studies suggest it does
(57). Also, the studies tend to highlight the nucleation properties of this species
rather than its elongation properties (57–59).

1.2.2.4

Mutations

There are over 80 known mutations associated with tau deposited in
various diseases, and many are in or near the MTBRs (60). The study of tau
mutations began through characterization of tau from a number of individuals
with familial FTDP-17 (61). In fact, the delineation that tau dysfunction is a cause
of neurodegeneration, rather than tau dysfunction being a symptom of disease,
was first made clear through the study of mutant tau (62). Mutations can have
their primary effect at either the RNA level or the protein level, and some
mutations have effects on both levels (24). Those mutations that have their
primary effect at the RNA level result in overproduction of either 4R or 3R tau
depending on the mutation, and thus alter the typically equimolar ratio of 4R/3R
tau present in the brain (24). This altered ratio serves as an explanation for the
preferential deposition of one isoform type over the other, yet not all mutations
8

cause altered splicing, so this is not a universal explanation. Specific mutations
that take their primary effect at the protein level can do so in a number of ways.
Some mutations are known to reduce the ability of mutated tau to interact with
MTs. This increased pool of monomers not performing their native function
increase the chance of aggregation (44). Mutations can also increase
aggregation propensity by not only reducing tau’s ability to interact with MTs, but
also make β-sheet packing more favorable (63). Additionally, studies utilizing
mutant tau for seeded growth reactions suggest that mutations also can impact
fibril core conformation (64). Due to the conformational templating growth
scheme of tau, which will be discussed in more detail in subsequent sections, the
ability of a mutation to promote conformational differences in fibrils is one
mechanism for some preferential deposition seen in diseases. This mutation
effect is explored in the work presented here. The wide range of pathological
features mutant tau is associated with speaks to the complexity of tau mutation
effects (65). Teasing apart the mechanisms by which these mutations lead to
preferential deposition seen in disease could help in understanding overarching
propagation principles.

1.3

Amyloids
1.3.1 Amyloid structure
Protein aggregates can be classified in many ways. Amyloid fibrils are one

type of classification, and tau fibrils are one subset of amyloid fibrils (66). The
9

association of amyloid fibrils with pathology in many diseases that have high
morbidity and mortality rates is one reason why they are so heavily researched.
A number of functional mammalian amyloid structures have been identified (67),
but fibrils associated with disease states continue to be highly studied. Most
proteins have the potential to form fibril-like structures under certain conditions.
However, it is the similar response to biochemical analyses, ability to fragment
and self-propagate, and common secondary structural characteristics that help
delineate fibrils as being amyloid (68, 69). Structural characterization of amyloid
fibrils began with the observation of their birefringence, suggesting a higher
structural order (70). This proved to be true upon electron microscopy
observations identifying dimensional features that allowed for morphological
distinction of these fibrils from other fibrillar protein structures (71). Ultimately Xray diffraction studies revealed that the core of amyloid fibrils share a common
cross-β substructure. Parallel to the long fibril axis are β-sheets and
perpendicular are β-strands, with consistent 4.8 Å spacing (72). A combination of
side chain interactions between monomers and hydrogen bonds oriented parallel
to the long axis stabilize this structure (73, 74). Additionally, tau fibrils have been
identified to have a parallel in-register arrangement of their β-strands, a structural
feature that is common to most amyloid fibrils (75). Figure 1.2 depicts a model of
such structure. All amyloid fibrils possess this structural cross-β characteristic,
but can differ in a more quaternary structural sense, for example how these fibrils
associate and pack with one another (69). They can also differ in their molecular
10

level structure, such as the folding pattern of the monomers making up the fibril
core. Different fibrils made up of the same protein monomer (or variant) can
have different core conformations, sometimes referred to as strains (76). This
concept of conformational variation will be discussed in more detail in
subsequent sections and has a major influence on propagation patterns.

Figure 1.2 Basic tau fibril structure A, model showing β-sheets are parallel to the

long fibril axis and β-strands are perpendicular with consistent 4.8 Å spacing. The
arrangement of strands is parallel in-register so identical residues (green dots) of
stacked monomers align with one another. B, electron microscopy image of tau
aggregates highlights their fibrillar nature. Scale bar = 200 nm.

1.3.2 Amyloid growth scheme
Amyloid fibrils are composed of protein monomers with diverse amino acid
sequences that are natively soluble, but upon association form fibrils which are
insoluble (77). The accepted model of amyloid fibril assembly is nucleation
dependent polymerization (NDP). NDP consists of an initial lag phase during
11

which nucleation processes occur, and a rapid growth phase (called elongation)
(78). Fibril assembly is commonly depicted with a simple graph showing the
fibrillar mass concentration, or aggregation, as a function of time (Figure 1.3).
Analyzing the kinetics in these types of graphs has led to the understanding and
ability to differentiate between different types of aggregation occurring, and
establish equations that based on properties of the specific protein and solution
can predict fibril growth in vitro (79). These plots differ greatly for different
proteins and different reaction conditions of the same protein (80). Integrated rate
laws are necessary to gain useful information from these types of plots due to the
fact that after initial nucleation begins, all processes are occurring simultaneously
(80). Also, these models can be more complex for the characterization of
intrinsically disordered proteins (IDPs), like tau, due to the unstructured nature of
their monomers (78).
Nucleus formation is typically the rate-limiting step. This is so because it is
thermodynamically unfavorable due to the competition between enthalpic gain,
from the formation of new contacts, and entropic loss, from the immobilization of
monomers into a fibril (81). Another limitation to nucleation of amyloid fibrils is the
inability to proceed without the existence of specific hydrophobic interactions,
that only occur with a specific protein sequence (82). For some proteins that
possess a native fold, exposure of the backbone groups allowing for hydrogen
bonds between protein monomers creating the cross-β structure is achieved by a
type of denaturation or misfolding event (83). Changes that thermodynamically
12

stabilize the transition from monomer to higher order species can include events
such as a concentration increase promoting tighter packing, or changes to steric
and hydrophobic interactions (84, 85). For in vitro tau aggregation studies, like
those presented here, an external factor is needed to induce aggregation
(nucleation and elongation) (86). Polyanionic cofactors are commonly used for
this in tau aggregation studies. These cofactors work to lower the energy barrier
of aggregation by charge compensation, with their negative charge
compensating for tau’s positive charge (81). While all the work presented here
utilizes heparin for this purpose, other factors such as RNA or arachidonic acid
have been used in other studies (86, 87).
The type of nucleation that initial fibril formation follows in the studies
presented herein is known as primary nucleation, referring to formation of an
oligomeric nucleus from only soluble protein monomers (81). Due to the fact that
initial fibrils for the majority of growth studies presented here were formed under
agitating conditions over multiple days, it is assumed that one type of secondary
nucleation, fragmentation, along with elongation both contribute to overall fibril
growth of initial fibrils once the formation of primary nuclei has occurred (81).
Other types of secondary nucleation, lateral growth or branching, are less likely
as no such characteristics were observed in the current study, nor in previous
work that used a similar growth protocol (21, 76, 88, 89).
Once nuclei have formed, the growth phase, also referred to as
elongation, can proceed by recruitment of monomer onto nuclei ends (80).
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Aggregation via elongation is much faster than aggregation via nucleation due to
the greatly decreased energetic barrier presented by monomer addition onto a
preexisting template (78, 90, 91). If rate equations governing fibril formation are
separated, the process for an elongation reaction, with no nucleation or
fragmentation but only addition of monomer onto pre-existing aggregates, can be
described with a maximal rate at the beginning of growth and decrease as the
concentration of free monomers is depleted over time (80). Importantly, growth
rate characterization has demonstrated that elongation occurs through monomer
addition to ends of preexisting fibrils (92).
Aggregation of initial fibrils for the current study included all steps of the
NDP growth scheme (Figure 1.3 A). However, once initial fibrils are formed they
can be fragmented and used as seeds to initiate new fibril growth and circumvent
the nucleation phase, this is commonly known as seeding (78) (Figure 1.3 B).
Experimentally forcing aggregation to immediately enter the elongation phase by
seeding is one way to study the growth properties of specific tau seed types (88).
As seeds recruit new monomers onto their ends during elongation, these
monomers assume the conformation of the seeds, thereby propagating the
structure of the particular fibril (93). If the monomer offered to grow on a specific
seed type is not compatible, or not able to assume that seed conformation, a
growth barrier will be observed. This technique of conformational templating via
seeded growth is employed in the majority of the studies presented here as a
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way to assess structure and growth properties of seeds composed of different
tau variants.

Figure 1.3 Kinetic distinction between nucleation vs seeded growth. A,

representative trace highlighting the lag phase during nucleation before
elongation occurs. B, representative trace of seeded fibril growth. Notice the
difference in time scales for A and B.
1.4

Conformational variation of tau fibrils
1.4.1 Strain phenomenon
The study of mammalian and yeast prions led to the discovery that

proteins themselves can be pathogenic through the transition from their native
non-disease state, into fibrillar aggregates associated with various disease
pathologies (94, 95). Studies on the propagation and transmissibility of these
fibrils revealed that fibrils made up of the same protein, but are different
conformations (strains), possess distinct pathological ramifications (96). This
phenomenon is also referred to as structural polymorphism, and can be used to
describe not only prions but amyloid fibrils such as tau (97). These
conformational variants all retain the cross-β structural characteristic with parallel
in-register β-sheet arrangement, but vary in the folding pattern of β-sheets and
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result in different fibril core conformations. Evidence that different tau strains, or
conformers corresponding to specific pathologies, was gained through studying
the pathology that resulted from injecting mouse models with tau fibrils extracted
from human brain material (98, 99). Specific pathology corresponding to tau
fibrils from humans with various tauopathies including AD, PSP, and CBD was
recapitulated upon injecting those fibrils into mouse models (100). This
phenomenon was further corroborated by the cryo-EM structures of tau fibrils
isolated from two different diseases, AD and PID. The structures revealed
different folding patterns for these fibrils (19, 20).

1.4.2 Distinct pathology and isoform specific deposition
Tau fibril aggregation commonly follows NDP, yet the affected brain
regions, morphology of the deposition, and even the types of isoforms present
can vary greatly between different tauopathies. AD is the most studied tauopathy
and therefore its progression and stereotypical spreading has been well
characterized and is referred to in Braak stages (101). Tau deposition in AD
patients presents as neurofibrillary tangles in the cell body and apical dendrites
of neurons, neuropil threads in distal dendrites and/or abnormal neurites
associated with some senile plaques, with affected brain regions including
frontal, parietal, and temporal lobes (102, 103). The paired helical (PHF) and
straight filaments making up these various deposits consist of a similar ratio of
4R to 3R isoforms, a distinguishing feature from other tauopathies (104). PID for
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example is referred to as a 3R tauopathy as the tau isoforms making up its
deposits are predominately 3R isoforms (105). PID is not only pathologically
distinctive, but presents with its own characteristic histological features including
cortical atrophy in the frontal and temporal lobes and severe neuronal loss,
ballooned neurons, and spherical inclusions referred to as Pick bodies
dominating the type of tau deposition (65), (106). There are also diseases that,
unlike AD and PID, can be characterized by deposition of predominantly 4R tau
isoforms. These include PSP, CBD, and Argyrophilic Grain Disease (AGD) (65).
Much like AD and PID, these diseases can be distinguished from one another by
distinct histological features, and their collective classification of 4R tauopathies
arises from the shared feature of 4R isoforms making up their unique forms of
deposition (65, 107–109). While the morphological and biochemical differences
between the tau deposition in these diseases are well documented, the
molecular mechanism of this preferential deposition still remains a question.
Some preferential deposition can be explained by mutations that result in
alternative splicing, therefore altering the ratio of 3R and 4R present in the brain;
however, this is not a universal explanation. Other factors suggesting this
preferential deposition have been identified, but it is still a pursued subject
because unraveling the mechanisms by which certain conformers propagate
would be universally beneficial to developing preventative therapeutics for tau
propagation.
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One mechanism aside from splicing to change 4R/3R ratios, arises from the
strain phenomenon discussed in the previous section. Strains (or fibril
conformers) that possess different physical properties, such as different growth
rates or different fragilities, allow for differential selection and preferential
propagation of certain strains over others. This was shown to be true for prions
(96) and later on for tau fibrils as well (76). How these different strains arise is
then a question of particular interest. Since fibrils spread from cell-to-cell, and
once transferred grow via conformational templating, the exploration of different
nucleating conditions that influence the structure of fibrils as they nucleate is one
way to probe this question (93, 110). This includes not only environmental
conditions such as pH and the presence of ROS influencing the extent of PTMs,
but also how particular mutations and truncations influence fibril structure. In
order to address questions concerning structural differences between fibrils, a
host of various biophysical and biochemical techniques has been employed.

1.5

Tau fibril detection and analysis techniques
1.5.1 Fibril detection techniques
Experimental detection techniques to assess the presence of tau fibrils

have existed for decades and are constantly being optimized to increase the
sensitivity of detection. Many such as tau-binding dyes Congo red and Thioflavin
(ThT), which were essential to initial tau discoveries, are still used today (111).
Other common tau detection techniques such as immunofluorescence and
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antibodies have been used since the 1980’s (9, 112). Antibody detection has
grown more sophisticated over the years to include conformer sensitive
discontinuous epitope antibodies (113, 114). The use of positron emission
tomography (PET) imaging with radiotracers is one method for early tau fibril
detection (115). Specific tracers for this technique are currently being developed,
and have shown promising results for targeting tau deposition in vivo (116).
These techniques and others are critical to many of the in vitro and in vivo
studies that have been performed and are currently taking place. There are also
a number of techniques that are able to simply determine the absence or
presence of fibrils by exploiting tau solubility. These include techniques like
sedimentation assays utilizing high speed centrifugation (21) or the use of
sarkosyl, a mild detergent that can distinguish soluble monomeric tau from
insoluble fibrillar tau (117).
Limited tau concentrations can be detected through the use of specific
antibodies. However, one of their limitations is in part due to the region of protein
being detected, and they are not always successful in distinguishing between
normal and pathological tau (113). Also, if fibrillar species are detected, the ability
to study the structure of these fibrils is limited by their small quantity. To utilize
structural analysis techniques that small population would need to be amplified.
Development of an assay that could selectively amplify only fibrillar species by
forcing a minute number of fibrils to elongate via conformational templating with a
pool of fresh monomer addressed both of these goals. This was achieved
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through adaptation of an assay from the prion field termed protein misfolding
cyclic amplification (PMCA) assay, and involves cycles of sonication followed by
incubation (118, 119). This same concept was then also applied to an assay
utilizing cycles of shaking followed by incubation in conjunction with ThT
fluorescence, termed real-time quaking-induced conversion or RT-QUIC assay
(120). This assay was also originally developed for the detection of prions and
was later applied to the detection of tau fibrils (121). These assays are
successful at detecting low fibril concentrations, but the ability to detect ultralow
concentrations is limited by the rate at which the monomer present begins to
spontaneously nucleate. Spontaneous monomer nucleation negates the selective
fibrillar detection aspect of the assay. Pushing the level of fibril detection to
ultralow concentrations would be exceedingly useful in developing early
diagnostic techniques that could detect tau fibrils from cerebrospinal fluid or
blood samples.

1.5.2 Assessing tau fibril structure
Optimizing detection techniques is critical for antemortem diagnosis, and
understanding the molecular level structure of the core of tau fibrils is also
important. Structural data could reveal fundamental mechanisms of fibril
propagation allowing for potential therapeutic design. A number of techniques are
used to indirectly reveal fibril core characteristics. When used in conjunction with
one another, these techniques have been successful in gaining insight into tau
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fibril structure. Some of these techniques, many of which are utilized for the data
presented herein, include seeded reactions (using various seed fibrils in
combination with different types of monomer, where incompatibilities in the
conformational templating results in growth barriers), visualizing proteolytic
cleavage fragments, denaturation profiles, fibril images obtained via negative
stain transmission electron microscopy (TEM), kinetics of fibril growth, or turbidity
(21, 76, 122, 123). These techniques reveal overall structural properties and
highlight structural differences, but alone they do not provide information with
enough resolution to make molecular level conclusions on the core structure of
tau fibrils. Some techniques that do gain molecular level insight into core
structure include electron paramagnetic resonance (EPR) techniques such as
site directed spin labeling (SDSL) in conjunction with continuous-wave (CW EPR)
or double electron-electron resonance (DEER) spectroscopy (76, 89, 124, 125).
Also, experiments assessing the effects of systematic point mutations and
truncations can be highly suggestive of the structural significance of particular
residues, and elucidate their role in core structure (21, 64). Förster resonance
energy transfer experiments, while not utilized in these works, have also been
successful in assessing fibril structure (126). High-resolution magic angle
spinning NMR and solid state NMR experiments have also been successful at
gaining structural insight into full-length and truncated tau fibrils, but have a
number of limitations (127, 128). Finally, cryo-EM has provided atomic level
resolution of fibrils extracted from human subjects (19, 20, 129). A host of
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molecular modeling software is also available to be used in combination with any
of these techniques, leading to enhanced structural insight (130, 131).

1.6

Scope of this research
The majority of my research presented in this current study involves

investigating the mechanism of tau fibril growth barriers by identifying structural
differences between fibrils that exhibit specific growth properties. The motivation
for these studies came from the gap in knowledge surrounding how tauopathies
present with such a wide range of pathological diversity (65), specifically the
preferential deposition of certain isoforms in particular diseases (4). Previous
works suggest conformational differences in fibrils to be one of the mechanistic
ways this disparate pathology arises (97), yet little molecular level core structural
data is known about the tau fibrils found in these diseases. Elucidating how
structural differences relate to growth properties is vital to understating fibril
propagation and finding a way to block it.
I began by optimizing growth conditions for full-length 4R tau (htau40) and
observed its growth properties were different from those previously observed for
truncated tau consisting only of the repeat regions, under otherwise similar
conditions (88, 130, 131). In order to determine the regions responsible for this
difference between truncated and full-length tau, I used 11 different truncated
variants with varying N- and C- terminal truncations. These truncated variants
were used to create seeds whose growth properties were tested. I also tested
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growth properties for a number of mutant full-length tau variants to try and
identify if mutations could be responsible for structural differences. CW EPR and
DEER spectroscopy techniques were also used to probe the structure of
particular truncated and mutant variants that exhibited 3R growth barriers.
To investigate whether or not manipulation of environmental conditions
could promote the formation of distinct fibril conformers, I isolated
intramolecularly disulfide bonded full-length 4R tau and tested its growth
properties. To identify if these oxidized fibrils were structurally distinct from their
full-length 4R tau counterpart lacking any disulfide bonds, I probed their
susceptibility to denaturants, patterns of proteolytic cleavage, and sensitivity to
fracture. I also investigated the structural significance of the disulfide bond in
these oxidized fibrils.
The remaining part of the work presented here is part of an ongoing effort
to improve the sensitivity of a minute fibril quantity detection assay, so that it can
be applied to blood or cerebrospinal fluid samples for early diagnostic purposes.
The goal was to develop a way to suppress spontaneous monomer nucleation
without diminishing monomer elongation competency. These monomers could
then be used to optimize amplification assay conditions for more sensitive
detection. I made a series of mutants we postulated would suppress primary fibril
nucleation due to their position in the hydrophobic core region of the protein. I
tested the quiescent nucleation of these mutants in comparison to non-mutant
full-length 4R tau. I also tested the elongation competency of these mutants
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through sedimentation and ThT kinetics assays. Mutants that were identified to
have an extended lag phase, and retained elongation competency, were
investigated further in conjunction with our amplification assay developed
previously in the lab (119). Optimization of this assay was pursued by measuring
responses to assay parameter changes in the hope that single fibril detection will
be possible.
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CHAPTER TWO: METHODS
2.1

Tau constructs
The primary 4R and 3R tau constructs used for these studies were

htau40, the longest 4R tau isoform containing 441 amino acids, and htau23 the
shortest 3R tau isoform containing 352 amino acids. The sequence of these two
isoforms along with their molecular weight, and the molecular weight of all
variants used herein are shown in Appendix C: Tau variants. These constructs
were previously cloned into pET-28 plasmids with Nco1/Xho1 restriction sites
and two stop codons preceding the Xho1 cloning site to remove the C-terminal
His6 tag (131). A number of truncated variants were also used, one variant
commonly used in other tau studies, K18, is the only variant with this type of
nomenclature. All other truncated variants are identified by the amino acids
contained in each given variant with numbering scheme according to htau40.
K18 was previously cloned in a similar manner to htau40 and htau23. All other
truncated variants were ordered from Biomatic Corporation as lyophilized pET-28
plasmid containing the gene insert. Variants with no further identification include
the native cysteines (positions 291 and 322) and no mutations. Two different
versions of cysteine free or cysless (CL) constructs were also used, in these
variants native cysteines were replaced by either serine or alanine. Unless
explicitly stated as htau40 SS (indicating the serine replacement) or htau40 AA
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(indicating the alanine replacement), experiments used serine replacement and
is notated as htau40 CL. Point mutations are identified by the original amino acid,
the residue number (with respect to htau40 sequence) and the new amino acid.
For example, P301S refers to the proline at position 301 in the full-length 4R tau
sequence being mutated into a serine, with native cysteines present.

2.2

Mutagenesis
Primers to make single point mutations were ordered from Integrated DNA

Technologies as lyophilized DNA oligomers. These primers along with template
DNA and QuikChange II Site-Directed Mutagenesis Kits (Agilent Technologies)
were used to make point mutations. Specifically, by combining 5 µL 10x reaction
buffer, 1 µL of DNA nucleotide bases (dNTP mix), 100-200 ng forward primer,
100-200 ng reverse primer, 20-30 ng stock DNA (DNA to be mutated), 29 µL
PCR certified water (Teknova), and 1 µL Pfu Ultra DNA polymerase and
subjecting that mixture to 17 cycles in a MJ Mini Personal Thermal Cycler (BIO
RAD). Each cycle consisted of three classic denaturing, annealing, and
extending stages at 95 °C for 1 min 15 seconds, 50-60 °C (5-7 °C lower than the
melting temperature of the primers) for 1 min, and 70-72 °C for 11 min
respectively. Following the completion of the cycles the reaction mixture was
brought to 4 °C after which 1 µL of Dpn1 restriction enzyme was added and let
incubate at 37 °C for 1 hour to digest parental DNA.
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2.3

Transformation
To obtain pure mutated DNA, digested PCR product was transformed into

cells optimized for plasmid preparation, E.coli XL1-Blue supercompetent cells
(Agilent Technologies). Transformation was carried out by combining 2 µL of
Dpn1 treated DNA with 25 µL cells in a round-bottom polypropylene tube
(Falcon) and set on ice for 30 min to allow plasmid to adhere to cell walls.
Plasmid permeation into the cell walls was achieved with a heat pulse in 42 °C
water for 45 seconds then placed back on ice for 2 min to prevent plasmid from
exiting the cells. Following those 2 min on ice, 600 µL of preheated (37 °C) NZY
mixture (10 g/L N-Z Amine (Sigma), 5 g/L Yeast (Difco), 5 g/L NaCl (J.T. Baker),
12.5 mM MgSO4 (Fluka), 12.5 mM MgCl2 (Sigma), 10 mM Glucose (Sigma)) was
added, and cells were grown for 1-1.5 hours shaking at 200 rpm in a 37 °C
incubator. Following growth, 200 µL of the NZY and cell mixture was plated onto
a Kanamycin (50 mg/L) LB agar culture plate (100 mm x 15 mm sterile
polystyrene, Fisher Scientific) and incubated at 37 °C for 15-20 hours. A single
colony from a culture plate was used to inoculate a mixture of LB medium (Miller,
BD) and Kanamycin (Gold Technology) that was placed in a 37 °C incubator
shaking at 200 rpm for 15-17 hours. After growth, these cells were harvested by
centrifugation at 6000 x g for 15 min and subjected to plasmid DNA purification
using Qiagen Plasmid MIDI kit following the Qiagen protocol. Pure DNA was sent
to Eton Bioscience for sequencing utilizing T7 promotor and T7 terminator
primers. Samples with the desired sequence were then transformed into cells
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optimized for expression, E.coli BL21 (DE3) cells (Agilent Technologies).
Transformation was carried out as described above with two exceptions, starting
with only 1 µl of pure DNA being combined with 25 µL cells, and only 50 µL of
NZY cell mixture being plated onto Kanamycin culture plates. The increased
transformation efficiency with pure DNA is the reason behind these changes,
plating 200 µL results in overgrowth on the plates and increased difficulty in
finding a single colony.

2.4

Expression and purification
Following transformation of pure DNA into E.coli BL21 cells, a single

colony from a plate was used to inoculate liquid bacterial culture. The single
colony was transferred to a mixture of LB medium (Miller, BD) with Kanamycin
(Gold Biotechnology) and let shake at 200 rpm for 15-17 hours. That starter
culture was then diluted 1:100 with sterile LB medium and Kanamycin (20 mg/L)
and let shake at 200 rpm and 37 °C until optical density reached 0.7-1 at 600 nm.
Protein expression was then induced by addition of 0.5 mM Isopropyl β-D-1thiogalactopyranoside (IPTG; Gold Biotechnology). Bacteria were incubated
shaking at 37 °C for another 3.5 hours before being pelleted at 3,000 x g and
homogenized in resuspension buffer (500 mM NaCl, 20 mM piperazine-N,N’bis(2-ethanesulfonic acid) (PIPES; Research Products International) pH 6.5, 1
mM ethylenediaminetetraacetic acid (EDTA; Fisher Scientific), and 50 mM βmercaptoethanol (Fisher BioReagents). Cells were then lysed using heat and
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sonication. Specifically, exposed to an 80 °C water bath for 20 min followed by tip
sonication (Fisher Scientific sonifier model 40:0.15:4C at 50% power with a
Branson 6-mm tip sonifer) for 1 min. The excessive heating from the 80 °C bath
and continuous sonication do not negatively affect tau because it is intrinsically
disordered. Once lysed, cell homogenate was centrifuged at 15,000 x g for 30
min to separate soluble protein from cellular debris. Soluble tau was then
precipitated by gently shaking with 55-60% w/v ammonium sulfate (MP
Biomedicals) for 3-20 hours at 25 °C. Precipitated tau pellets from a 15,000 x g
spin were taken up in H2O with 2 mM dithiothreitol (DTT; Gold Biotechnology),
sonicated for 2 min (at 50% power on the same sonicator used previously),
syringe filtered (GxF/GHP 0.45 µm) and loaded onto a cation exchange column
(mono S 10/100 GL; GE Healthcare). Cation exchange can be used because tau
carries a net positive charge, for example the isoelectric points for htau40 and
htau23 are 8.4 and 9.4 respectively. Once loaded onto the MonoS column,
proteins were eluted using a linear NaCl Gradient (50-1000 mM NaCl, 20 mM
PIPES pH 6.5, 2 mM EDTA) and fractions were pooled based on SDS-PAGE
with Coomassie stain assessment (representative chromatograph and gel shown
in Appendix A). For further purification, pooled ion exchange fractions were
loaded onto a Superdex 200 or Superdex 75 (GE Healthcare) gel filtration
column and eluted with 100 mM NaCl, 20 mM Tris (Sigma), 1 mM EDTA and 2
mM DTT buffer pH 7.4 (representative chromatograph and gel shown in
Appendix A). Fractions were again assessed using SDS-PAGE and those
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containing pure tau were pooled. Tau from these pooled fractions was
precipitated overnight at 4 °C using either a 1 volumetric equivalent of methanol
or 3-fold volumetric excess of acetone depending on the length of the tau variant
being purified, along with 5 mM DTT. Variants containing fewer than 200 amino
acids were run over the Superdex 75 column and precipitated using acetone.
Those larger than 200 amino acids were run over the Superdex 200 column and
precipitated using methanol. Following precipitation, pellets were collected with a
15,000 x g spin for 10 min, transferred to 2 mL Eppendorf tubes, and centrifuged
for 10 min at 13,500 x g. Supernatant was removed and pellets were spun again
with 1 mL fresh methanol or acetone to completely exchange any buffer present.
Pellets were then stored in methanol or acetone with 2 mM DTT at -80 °C until
further use.

2.5

Monomerization
Precipitated protein pellets need to be solubilized into monomeric form, in

an appropriate buffer, before use. Pellets being stored at -80 °C were taken from
the freezer and all the methanol or acetone they were stored in was fully
removed. Protein pellets were then dissolved in 200 µL of 8 M guanidine
hydrochloride (GdnHCl; Thermo) for 2-5 hours. Once fully dissolved, denaturant
was removed using a PD-10 desalting column (GE Healthcare). The total volume
of dissolved protein solution was applied to one column followed by a volume of
assembly buffer (100 mM NaCl, 10-40 mM 4-(2-hydroxyethyl)-130

piperazineethanesulfonic acid (HEPES; J.T. Baker) and 0.1 mM NaN3 (Fisher
Scientific) at pH 7.4) that would make a total volume of 2 mL between dissolved
protein and buffer. These 2 mL were allowed to fully enter the column. Protein
was then eluted with 2 mL of assembly buffer. Before and after use, columns
were cleaned by applying 200-300 µL of 6 M GdnHCl followed by 40-60 mL of
assembly buffer to each column. Between runs columns were stored in
assembly buffer, and discarded after approximately 20 uses. Concentration of
eluted protein was determined using bicinchoninic acid assay (BCA assay;
Thermo Fisher Scientific). The Pierce BCA Protein Assay Kit protocol was
followed, and a standard curve with BSA was used each time. Extinction
coefficients were not used for concentration determination because there are no
tryptophans and only 5 tyrosines in even the longest 4R isoform. Once
concentration was determined 0.5 mM tris(2-carboxyethyl)phosphine (TCEP;
Gold Biotechnology) was added to cysteine containing variants to prevent
disulfide bonding. Some experiments, where disulfide bond formation was
desired, are exempt from this TCEP addition. Protein was then either flash frozen
in aliquots appropriate for future experiments, or kept on ice at 4 °C for more
immediate usage.

2.6

Initial fibril formation
Initial fibril formation (seed formation) was achieved by incubating a 500

µL mixture of 25 µM tau, 50 µM heparin (Celsus, average molecular weight 4400
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kDa), 0.5 mM TCEP and assembly buffer stirring with a teflon-coated micro stir
bar (5x2 mm) at 160 rpm for 7-8 days at 37 °C. Tubes with a flat bottom
(MultiMax microcentrifuge tubes) were used so the stir bar could freely rotate.
Heparin (or another polyanionic cofactor) is necessary for any aggregation, both
initial fibril formation and seeded growth. Variants that did not contain any
cysteines, or were oxidized, did not include TCEP during initial fibril formation. To
ensure fibril formation, after 7-8 days 100 µL was taken from the mixture and
centrifuged for 30 min at 128,000 x g (Beckman L7-55 ultracentrifuge). Any pellet
was separated from supernatant and volumes were adjusted using SDS sample
buffer (62.5 mM TRIS pH 6.5 (Sigma), 4% SDS (J.T. Baker), 10% sucrose (MP
Biomedicals), 5% 2-Mercaptoethanol (βME; Fisher Scientific), 1.5 mM
Bromophenol Blue (Sigma)) so equal sample amounts could be analyzed by
SDS-PAGE with Coomassie staining. 12% or 15% gels were used depending on
the length of the variant making up the fibrils. Seed fibrils that showed majority
growth (quantified via Image J software as described below in Growth Analysis)
and little to no degradation were used for seeded reactions.

2.7

Seeded sedimentation reactions
To create fibrils fragments, or seeds, fibrils grown as described above

were subjected to 30 second sonication on ice at 20% power (4 ± 1 w(RMS)) with
a Fisher Scientific sonifier (model 100 with a 2 mm tip). The 2 mm rather than 6
mm tip was used simply because the larger tip did not fit inside the seed tube.
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Seeded reactions were carried out using these seeds (10% monomer molar
equivalent) in combination with fresh 10 µM tau monomer, 20 µM heparin, 0.5
mM TCEP and assembly buffer, and let incubate quiescently at 37 °C for 20-24
hours. TCEP was not used in the majority of reactions containing oxidized tau,
other deviations are noted in the text. After incubation, reactions were
sedimented using a 30 min centrifugation at 128,000 x g. Sedimentation caused
long fibrils to be pelleted, and monomers unable to be incorporated onto seeds,
along with seeds that had no monomer grow on them to remain in the
supernatant. Following centrifugation, pellet and supernatant were separated and
both analyzed using SDS-PAGE with Coomassie staining as described in section
2.6.

2.8

Growth analysis
Image J software was used on scanned gels to assess the amount of fibril

growth for a given reaction. This was done by dividing the pixel density of protein
band in the pellet lane by the added density of both the pellet and supernatant
lane. These values (multiplied by 100) are reported in all box-and-whisker or
scatter plots as a percentage growth. 100% would represent a reaction where the
entire protein density appeared in the pellet lane while 0% appeared in the
supernatant lane. Data points for a given reaction condition represent results
from reactions initiated from different seed batches (biological replicates), not
multiple reactions initiated from the same seed batch (technical replicates). Plots
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were created using GraphPad Prism 7 software where statistical significance
between growth from different reactions is determined using a paired t-test. Pvalue summary for each comparison is shown as stars (**), and the p-value that
corresponds to the specific number of starts is in the legend for each specific
figure. Box-and-whisker plots utilize the Tukey method for displaying whiskers
and outliers, and lines on scatter plots indicate mean with standard deviation.

2.9

Thioflavin T kinetics
Thioflavin T (ThT, Sigma) is a dye that fluoresces upon binding to amyloid

fibril core structure (111) and was used to monomer fibril growth kinetics. These
reactions contained 10 µM tau, 20 µM heparin, 5 µM ThT, 5% or 10% seed
(overall 0.5 µM or 1 µM tau in sonicated fibril form) and assembly buffer. Unless
oxidized variants were used, these reactions also contained 0.5 mM TCEP. The
only time TCEP was used in conjunction with oxidized monomer/fibrils was as a
treatment in the dissociation experiments, as noted in the text. Fibril growth was
monitored in real time by thioflavin T fluorescence using a BGM Labtech
FLUOstar Omega plate reader utilizing excitation/emission wavelengths at
440/480 nm and constant 37 °C. Readings were taken through the bottom of a
Thermo Scientific 96 well optical Btm Plt PolymerBase plate. Some reactions, as
indicated in figure legends, utilize a 2 second 100 rpm shake prior to the first
reading to ensure reactions are mixed. Growth reactions were done in either
triplicate or quadruplicate and the average values along with their standard
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deviation (S.D.) are displayed for each reaction. Due to the different ways ThT
can bind to different conformers resulting in different total fluorescence, intensity
growth rates rather than end point intensity were used in some cases to compare
different reactions. Growth rates were compared by the time it took ThT intensity
to reach half its max value and are reported as T ½ values.

2.10 Transmission electron microscopy
Transmission electron microcopy was used to visualize aggregation from
different reaction conditions. Formvar/ Carbon 200 mesh copper grids (Electron
Microscopy Sciences) were exposed to a droplet containing approximately 2.5
µM fibrils for 1.5 min, blotted on filter paper to remove excess liquid, exposed to a
droplet of 2% uranyl acetate (Electron Microscopy Sciences, 0.2 µm syringe
filtered) for 1.5 min, and again blotted on filter paper then let air dry for
approximately 5 min before being stored in holder until imaging. Fibril images
were recorded at University of Colorado, Boulder with a FEI Tecnai T12 Biotwin
Electron transmission microscope using a high tension of 100 KV and equipped
with a Gatan CCD camera. The negative stain TEM images were taken by myself
with the exception of those shown in Chapter 3 which were taken by Dr. Michael
Holden. Quantification of seed length was done by analyzing micrographs of
sonicated seeds using Image J software utilizing the scale bar on the image to
calibrate the number of pixels to an accurate length. These lengths were then
binned and plotted in GraphPad Prism 7.
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2.11 MTSL labeling of tau
Electron paramagnetic resonance (EPR) experiments were performed to
gain insight on side-chain stacking and structural rigidity of tau protein, and to
determine distances between paramagnetic centers in a sample (124). The
paramagnetic spin label used for all continuous wave (CW) EPR and double
electron-electron resonance (DEER) spectroscopy experiments was [1-oxyl2,2,5,5-tetramethyl-Δ3-pyrroline-3-methyl]methanethiosulfonate (MTSL; Toronto
Research Chemicals). This label covalently binds to a cysteine residue as shown
in Figure 2.1 (132). To ensure specific labeling, variants to be used for EPR
experiments had native cysteines mutated into serines, and cysteines mutated in
only the desired labeling position. Protein pellets being stored at -80 °C were
taken from the freezer and all the methanol or acetone they were stored in was
fully removed. Protein pellets were then dissolved in 200 µL of 8 M guanidine
hydrochloride (GdnHCl; Thermo) for 2-5 hours. Once fully dissolved, MTSL
(taken up from powder form in DMSO to 40 mg/ml) was added in approximately
10- fold molar excess. Labeling reaction took for place for at least 1 hour while
sitting in the dark quiescently at 25 °C. Excess label was then removed, along
with denaturant, when passed over PD-10 columns as described in Section 2.5.
The non-paramagnetic analog of MTSL [1-acetyl-2,2,5,5-tetramethyl-Δ3pyrroline-3-methyl]methanethiosulfonate (Toronto Research Chemicals) was
attached in a similar manner and used for dilution of some CW EPR samples.
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Figure 2.1 MTSL labeling of tau. MTSL spin label covalently links to a single

cysteine residue.
2.12 CW EPR sample preparation
CW EPR spectra of monomers were taken to confirm MTSL had bound to
monomer and was in a fairly mobile state. This is indicated by spectra with three
sharp and narrow peaks with a 34 G outer peak separation (133). These spectra
were collected at X-band (9.5 GHz) at 25 °C with 150 G sweep width, 12.05 mW
power and 1 G modulation amplitude on a Bruker EMX Plus spectrometer fitted
with an ER 4119HS resonator. Once monomer was confirmed labeled with
MTSL, fibrils were formed by allowing a combination of 30 µM MTSL labeled
monomer (either 100% paramagnetic MTSL labeled, or 20% paramagnetic MTSL
labeled/ 80% non-paramagnetic MTSL labeled monomer), 15 µM heparin, 5%
seed not labeled with MTSL (formed as described above in Section 2.6), and
assembly buffer to quiescently incubate at 37 °C for 20-24 hours. Following
incubation, fibrils were sedimented in a 128,000 x g 30 min spin after which
supernatant was fully removed. Pelleted fibrils were gently mixed with 10 µL
fresh assembly buffer in order to be loaded into round capillary tubes (Vitrotubes
0.6 ID x 0.84 OD).
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2.13 CW EPR sample measurement and analysis
Tubes containing fibrils to be analyzed via CW EPR were inserted into the
resonator such that the sample was centered vertically or filling the length of the
resonator. Spectra are an average of 20 scans collected at room temperature
with 150 G sweep width, 12.05 mW power, 3 G modulation amplitude,
modulation frequency of 100 KHz, 5.02 x 103 receiver gain, 81.92 msec time
constant, 20 msec conversion time, 1 harmonic, with 1024 x resolution on a
Bruker EMX Plus spectrometer fitted with an ER 4119HS resonator operating at
X-band. Spectra being compared were normalized to the same number of spins
using double integration so amplitudes could be compared. These amplitudes
are reported in histogram form for comparison between different monomer
(differing by which residue was labeled) grown onto different seeds. Bars
represent averages and error bars represent standard deviation from biological
triplicate measurements for each reaction type.

2.14 DEER sample preparation
DEER samples were prepared by combining 48 µM non MTSL labeled tau
(CL variants), 2 µM tau double MTSL labeled at positions 311 and 328, 10%
seeds, 12.5 µM heparin and assembly buffer then incubating quiescently at 37 °C
for 24 hours. Seeds were assembled as described in section 2.6, and fibrils
indicated as mutant are 100% mutant meaning the tau used in the 48 µM non
MTSL labeled, 2 µM MTSL labeled and seeds all contained the mutation of
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interest. Following incubation, fibrils were sedimented for 30 min at 128,000 x g,
supernatant was removed, and pellets were mixed with 10-15 µL of fresh
assembly buffer for transfer into quartz Q-band tubes (VITROCOM SFS round
cell 1.1 mm ID). Samples were then analyzed to ensure proper label
incorporation using CW EPR (as described above) before being flash frozen and
stored at -80 °C until DEER measurements could be performed.

2.15 DEER sample measurement and analysis
DEER measurements were collected at Q-band (34 GHz) using a fourpulse sequence depicted in Figure 2.2. A field-sweep spectrum was used to
center the operating frequency (ν1), and the pump frequency (ν2) was adjusted to
37 MHz below ν1. For each experiment the gate and τ-0 were optimized and
ranged between 64-72 ns and 910-914 ns respectively, and the π/2 pulse at ν1,
the π pulse at ν2, τ1, τ2 and τ3 and τx remained constant at 16 ns, 32 ns, 200 ns,
3000 ns, 100 ns and 8 ns respectively. The shot repetition time was optimized for
each sample to be 1.2 x T1 (spin-lattice relaxation time) and signal averaging
took place for approximately 24 hours per sample with each scan containing 8
step phase cycling to remove unwanted echoes. Data was collected using a
Bruker ELEXSYS E580 spectrometer with an ER 5107D2 dielectric resonator, a
580-400U ELDOR unit as the second microwave source and a 10 W amplifier.
Temperature was kept at 80 K using an Oxford CF935 cryostat and liquid
nitrogen. Data were analyzed with DEER Analysis 2018 (134) using Tikhonov
39

regularization, three-dimensional homogenous background fit, programoptimized selection utilizing validation tool for zero time, background time,
regularization parameter, and phase, whereas cutoff time was kept constant for
each sample at 2936 ns.

Figure 2.2 DEER pulse sequence. The echo formed after two pulses at ν1 is

refocused and decays with time after the third pulse. A separate part of the
spectrum is excited by the fourth pulse at ν2. If there is interaction between the
two sets of spins at the frequencies ν1 and ν2 the strength of the interaction
between the spins reveals information about the distance between them.

2.16 Oxidation of tau
The majority of experiments were done in the presence of reducing agent
so disulfide bonds are not formed. However, some experiments wanted to
explore the effect of intramolecularly disulfide bonded monomers. These
monomers required further preparation following monomerization before
experimental usage. Oxidation of htau40 was carried out by incubating 20 µM
htau40 immediately following its monomerization with 5 mM H2O2 (Sigma-Aldrich
30% (w/w) in H2O) at room temperature in the dark for 16-20 hours. To remove
H2O2, and promote any oxidation that has not already occurred, the reaction was
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then transferred into a dialysis tube (Spectra/Por flat width 10 mm, molecular
weight cutoff 12-14 kDa) and let dialyze over 2-3 rounds of suspended agitation
in 1 L 40 mM HEPES assembly buffer each for 1 hour at 5 °C. Following dialysis,
the reaction was spin concentrated using Amicon Ultra centrifugal filter units
(molecular weight cutoff 10 kDa) to a final volume 1.5-2 mL. This volume was
desired given the capacity of the size exclusion column being used in the next
step. Spin concentrated protein was run over a size exclusion column (GE
Healthcare Superdex 200 10/300 GL) to separate higher order species from
monomer, using 0.5 mL fraction size and 40 mM HEPES assembly. To identify
fractions containing only monomeric intramolecularly disulfide bonded htau40
from those with some higher order intermolecularly bonded species, fractions
were run on a regular SDS-PAGE gel. Importantly SDS sample buffer with no
reducing agent was used because disulfide bonds needed to remain intact.
Fractions containing only monomeric species with an intramolecular disulfide
bond were pooled and a concentration was determined using BCA assay. To
confirm the cysteines in this monomer are not free, this oxidized monomer was
subjected to the protocol for MTSL labeling of tau (as described in Section 2.11).
The lack of strong MTSL signal in a CW EPR spectrum following the labeling
protocol confirms cysteines are not free. The reversibility of the disulfide bond
was confirmed by the restoration of signal from oxidized monomer that was
incubated with 20 mM DTT for 5 hours then had the DTT dialyzed out (in the
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same manner as described above for dialysis), before being subjected to the
protocol for MTSL labeling of tau.

2.17 Anaerobic sedimentation reactions
One set of sedimentation reactions, described in detail in Chapter 4, was
carried out in the absence of oxygen. These experiments used Coy Lab Products
anaerobic chamber and glove box. Oxygen content was kept between 10-20
parts per million using a Coy Anaerobic Monitor (CAM-12 detector) and
compressed gas (nitrogen and hydrogen). Buffer to be used was purged with
compressed nitrogen gas for 30 min prior to entering the chamber. After
dissolving an htau40 precipitated pellet in ambient room conditions with GdnHCl,
the dissolved protein was taken into the chamber where it was run through a
PD10 column in the same manner as described in Section 2.5. Following elution
off the column protein dilutions for BCA assay concentration determination were
made and removed from the chamber for measurement. Once concentration was
determined, the monomer (10 µM) was used for reaction setup inside the
chamber with nitrogen purged buffer along with heparin (20 µM) and 10% seeds.
Heparin and seeds were in tubes opened inside the chamber for 15 min prior to
use. Once reaction components were combined the reaction tubes were placed
in a digital dry bath set to 37 °C inside the chamber and let incubate for 20-24
hours. Following incubation, they were removed from the chamber and
sedimented (30 min at 128,000 x g). Following sedimentation pellets separated
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from supernatants and run on SDS-PAGE gels with Coomassie staining, then
analyzed as previously described. This anaerobic experimental setup only
applies to the data shown in Figure 4.6 B. The ambient oxygen content for all
other experiments does not impact the results because reducing agent is present
for experiments where no disulfide bond formation is desired, hydrogen peroxide
was used to oxidize variants that did desire disulfide bond formation, and the
slow oxidation (via dissolved oxygen content) of cysteine containing variants in
reactions absent of reducing agent is part of the experimental question and is
noted in the text in Chapter 4.

2.18 Guanidine melt of fibrils
Denaturation profiles were used to highlight structural differences between
fibril types. Homotypic growth reactions utilizing 10% htau40 reduced or oxidized
seeds were set up (as described in 2.7) and let incubate quiescently at 37 °C for
20-24 hours. Following incubation, a 100 µL aliquot of this growth was
centrifuged and assessed using SDS-PAGE to confirm grown (presence of
protein exclusively in the pellet) for each reaction mixture. Once growth was
confirmed growth mixtures were aliquoted into seven tubes to which the same
volume of solutions with various GdnHCl (Thermo) concentrations were added.
The different final concentrations of GdnHCl in each aliquot were 0, 0.1, 0.25,
0.5, 0.75, 1, or 1.5 M GdnHCl. The contents of the tubes were mixed and let
quiescently incubate at 25 °C for 1 hour. Following incubation, these mixtures
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were centrifuged for 30 min at 128,000 x g, supernatant was discarded, pellets
were taken up in 100 µL SDS sample buffer. These were then run on SDS-PAGE
gels with Coomassie staining to assess the quantity of protein found in each
pellet fraction. The amount of protein remaining fibrillar and present in the pellet
fraction following this protocol was quantified using Image J software as
described in Section 2.8. For each fibril type the average values corresponding to
the remaining fibril content at each GdnHCl concentration, from biological
triplicate measurements, are depicted in a scatter plot.

2.19 Limited proteolysis
Limited protease digestion was used to highlight differences in fibril
structures by comparing their pattern of cleavage products on SDS-PAGE gels.
Homotypic 10% seeded growth reactions for htau40 reduced and oxidized fibrils
were assessed for growth as described in Section 2.18. Following growth
confirmation, 80 µL aliquots of each fibril type were treated with 60 nM proteinase
K (PK; Promega) or assembly buffer (in the same volume as PK in parallel
reactions) at 25 °C for 30 min. Proteolysis was stopped with the addition of 4 mM
phenylmethylsulfonyl fluoride (Sigma). SDS sample buffer was then added and
samples were run on a 4-20% precast gradient gel (Bio-Rad Mini-PROTEAN
TGX stain-free gels) and stained with Coomassie.
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2.20 Limited sheering of fibrils
Differences in fibril fragility was used to highlight their structural
differences. Homotypic 10% seeded growth reactions of htau40 reduced and
oxidized fibrils were assessed for growth as described in Section 2.18. Following
growth confirmation, 100 µL aliquots of growth mixture were subjected to 30
seconds of sonication in a Qsonica bath sonicator at 5% power (specifics on this
sonicator are in section 2.24). Bath sonication rather than tip sonication was used
because it produced the milder sheering needed for this experiment. Following
sonication, aliquots were diluted with assembly buffer to approximately 2-2.5 µM
and loaded onto Formvar/ Carbon 200 mesh copper grids for TEM imaging and
analysis as described in Section 2.10.

2.21 Crosslinking htau40 monomer
Observing growth properties of htau40 monomer with something other than
a disulfide bond linking the two native cysteines was desired. The bismaleimide
crosslinker used to link native cysteines in htau40 monomer is shown in Figure
2.3. Methanol was removed from a pellet of precipitated htau40 before being
dissolved in 2 mL of GndHCl. Once dissolved, an approximate 3-fold molar
excess of bis(maleimido)ethane (BMOE; Thermo Scientific, taken up in DMSO to
20 mM) was added and let incubate at 25 °C in the dark quiescently for 1 hour.
Following incubation, 500 mM DTT was added to quench any unbound label,
then the dissolved protein containing crosslinker was run in ~500 µL aliquots
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over PD10 desalting columns and eluted as described in Section 2.5. The protein
containing elution fractions were spin concentrated to a final volume of 2 mL
before being run over a size exclusion column (GE Healthcare Superdex 200
10/300 GL) utilizing 0.5 mL fraction size and 40 mM HEPES assembly buffer pH
7.4. To distinguish fractions containing monomeric crosslinked species from
higher order species, fractions were run on SDS-PAGE gels. Fractions
containing only monomeric species were pooled and a concentration was
determined using BCA assay.

Figure 2.3 Bismaleimide crosslinker. Structure of bis(maleimidio)ethane, BMOE,

which will crosslink two cysteine residues with an 8 Å spacer arm.

2.22 Dissociation of htau40 oxidized fibrils
The dissociation of oxidized fibrils was investigated by treating them with
reducing agents. Growth of homotypic htau40 oxidized seeded reactions (setup
described in section 2.7, with no TCEP present initially) were allowed to proceed
for 5 hours at which time the reactions were removed from the 37 °C incubator
and treated or sedimented. Treatments to each reaction were made with the
same volume of different stock solutions to achieve different final reducing agent
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concentrations. For control reactions the same volume of assembly buffer was
added. The treated reactions were gently inverted once then returned to the 37
°C incubator to quiescently sit for 16-20 hours. Following incubation, the
reactions were spun down in a high-speed spin (as described in Section 2.7) and
20 µL of the supernatant along with pellet fraction were assessed for percent
growth by protein band quantification on SDS-PAGE gels. In some cases, the
remainder of the supernatants, approximately 980 µL, were run over a size
exclusion column (GE Healthcare Superdex 200 10/300 GL) to compare the
elution peak patterns of the protein that supernatant. In a similar manner, 980 µL
of 5 µM htau40 (with 0.5 mM TCEP present) was also run over this column as a
control to confirm the elution volume of htau40 monomer peak. From each run, 6
µL of the 1 mL fractions from the elution volume were run on SDS-PAGE gels to
observe and compare the banding patterns.

2.23 Monitoring quiescent nucleation
Hexapeptide mutants were investigated for their potential to suppress selfnucleation, a critical factor for use in our amplification assay. These mutants
were made as described in Section 2.2. These mutants along with htau40
monomer were used in 200 µL reactions (25 µM monomer, 50 µM heparin, 5 µM
ThT, and 1 mM TCEP with 40 mM HEPES assembly buffer) to quiescently
monitor self-nucleation. These reactions were monitored in a 96-well clear
bottom polymerbase plate (Thermo Scientific) and fibril content was monitored in
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real time by ThT fluorescence using a BGM Labtech FLUOstar Omega plate
reader utilizing excitation/emission wavelengths at 440/480 nm and constant
temperature of 37 °C. Readings were taken in several hour increments over
multiple days. Variation between runs included some plates being kept in a 37 °C
incubator between readings, while some plates remained in the plate reader at
37 °C for the entirety of the experiment. ThT fluorescence readings were plotted
in Excel as an average of three measurements.

2.24 Amplification assay
An amplification assay consisting of cycles of sonication and incubation was
used to measure spontaneous monomer nucleation and/or growth from seeded
reactions. Not all reaction component/parameter variations are shown in figure
form, but some are listed in table format in Appendix B. However, specific
reaction components for data shown in figures were 10 µM monomer, 40 µM
heparin, 1 mM TCEP brought to a final volume of 200 µL with 40 mM HEPES
assembly buffer. Seeded reactions additionally had htau40 seeds present; seed
formation was done as described in Section 2.6 then diluted so the same final
volume was added to each reaction for different final seed concentrations. Each
seed dilution had heparin to a final concentration of 40 µM and TCEP to a final
concentration of 0.5 mM. Reactions took place in nontreated black bottom 96
microwell plates (Thermo Scientific). Plates were sealed with certified DNaseRNase- free clear polyolefin sealing tape (Thermo Scientific) and floated in 700
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mL of water in a microplate horn coupled to an ultrasonic processor (Qsonica)
with a temperature control unit (Qsonica model 10-180-GI-PI-08S) to keep all
experiments at a constant temperature of 37 °C. Individual parameters that
varied between different experiments include the sonication time, incubation
time, power amplitude of sonication, tau concentration and heparin
concentration. Specific parameters for individual experiments can be found in
Appendix B or in the text of Chapter 5. Following cycles of sonication and
incubation, reactions were transferred to 1.5 mL Beckman Coulter centrifuge
tubes and centrifuged at 128,000 x g for 30 min, pellets were separated from
supernatants and analyzed by SDS-PAGE with Coomassie staining as described
in Section 2.6.
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CHAPTER THREE: TRUNCATIONS AND MUTATIONS AFFECT CORE
CONFORMATION IN FOUR-REPEAT TAU FIBRILS

3.1

Formation of seed fibrils
Recruitment of tau monomers onto fibrils is a conformation-dependent

phenomenon. This means if monomers are incompatible with a specific seed
fibril conformer, they will not add on to elongate those fibrils. One potential
mechanism causing the preferential deposition of 3R or 4R tau in some
tauopathies is a conformation-based cross seeding barrier. This theory was
investigated by testing the growth properties of different tau fibrils. Specifically, if
truncated and mutated 4R tau variants could form different fibril conformers from
full-length non-mutated 4R tau. In order to probe the elongation properties of
specific fibrils, these fibrils had to first be formed. Initial fibrils were formed
through the NDP growth scheme (nucleation and elongation) of specific
monomeric tau variants, over several days through agitation at 37 °C in the
presence of a polyanionic cofactor (heparin) and reducing agent (TCEP).
The first variant to be characterized was htau40. Initial growth of long
unbranched fibrils was confirmed using negative stain transmission electron
microscopy (TEM) (Figure 3.1 A). These fibrils were then sheared using a tip
sonicator to create shorter fibril fragments referred to as seeds (Figure 3.1
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B). The seeds were roughly the same length, as a distribution of their quantified
lengths proved to be a fairly narrow distribution with an average of 39 nm (Figure
3.1 C). An indirect representation of this transition from long fibrils to short fibril
fragments is the fraction they end up in following centrifugation at 128,000 x g,
with visualization by SDS-PAGE and Coomassie staining. Identical centrifuge
parameters cause long unbroken fibrils to experience a higher centrifugal force
and transition into in a pellet, but the short seed fragments remain in the
supernatant as the force they experience is not great enough to sediment them
(Figure 3.1 D). The presence of the protein at the expected size for htau40 on
SDS-PAGE suggests this sonication event is acting to disrupt the stacking of
monomers within the long fibrils, not destroying the individual monomers. If the
sonication event was acting to break apart monomer, protein would be observed
as having a lower weight on SDS-PAGE, and it is not. Once the protocol was
established for the creation of seeds, experiments to explore the recruitment
properties of those seeds were pursued.
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Figure 3.1 Characterization of htau40 fibrils. A and B, EM images of htau40 fibrils
formed via nucleation and elongation before (A) and after (B) tip sonication. Scale bars =
100 nm. C, distribution showing quantified htau40 seed lengths. D, SDS-PAGE with
Coomassie staining assessment of P = pellet and S = supernatant fractions of
unsonicated and sonicated fibrils following centrifugation. This demonstrates that initial
growth results in long fibrillar structures, which after tip sonication, show uniform
fracture.

3.2

Growth of htau40 and htau23 monomer onto htau40 seeds
Growth properties of fibrils made up of the longest 4R isoform, htau40,

were the first to be investigated. The ability of these htau40 seeds to recruit both
4R (htau40) and 3R (htau23) tau monomers was in question (Figure 1.1).
Reactions contained 10% (molar monomer equivalence) of seeds combined with
fresh htau40 or htau23 monomers (10 µM) along with reducing agent (0.5 mM
TCEP) and heparin (20 µM). These reactions were allowed to quiescently
incubate at 37 °C for 20-24 hours. Following the incubation period, reactions
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were spun down and pellets were separated from supernatants before both were
run on 12% SDS-PAGE gels. Growth assessment was done by comparing the
percentage of protein in the pellet vs the supernatant for each given reaction, and
results show that htau40 seeds fully recruit both 4R and 3R monomer (Figure 3.2
A). SDS-PAGE analysis shows the protein band from htau40 seed in the pellet
for the reaction with htau23 monomers because the initial short seed fragments
were elongated, and are part of the long fibrils being sedimented. This growth
trend of htau40 recruiting both 4R and 3R monomers is highly reproducible as it
was seen for >40 biological replicates (Figure 3.2 B). Biological replicates refer to
reactions initiated from different seed batches. Thioflavin T (ThT) fluorescence
can also be used to highlight the growth of these monomers onto htau40 seeds
(Figure 3.2 C). The difference in end point fluorescence for each reaction can be
attributed to the different ways in which ThT binds to the monomers making up
the fibrils, however the significant point is the growth rates of these reactions are
similar. This similar rate is shown by the comparable time it took each reaction to
reach half maximum intensity (Figure 3.2 C), suggesting no preferential growth of
4R or 3R monomer. The lack of a lag phase and the absence of fluorescence
increase for reactions incubated in the absence of seed, in agreement with
previous observations (93), confirm that the aggregation seen in these seeded
reactions is via elongation onto those seeds and not spontaneous monomer
nucleation. Additional independent confirmation that the aggregation is fibrillar,
not amorphous, was achieved by TEM (Figure 3.2 D).
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Figure 3.2 Seeding properties of htau40 fibrils. A, SDS-PAGE with Coomassie
staining of 10% htau40 seeded reactions with htau40 monomer or htau23 monomer. P =
pellet, S = supernatant. B, box-and-whisker plot displaying results from quantified growth
from seeded reactions, n = number of biological replicates. C, average ThT fluorescence
showing kinetics of htau40 (blue) and htau23 (red) monomer growth on htau40 seeds,
and monomer controls (green) in the absence of seeds. Error bars represent standard
deviation (S.D.) from triplicate measurements. D, negative stain TEM images of growth
from htau40 seeded reactions with htau40 (left) and htau23 (right) monomers. Scale
bars = 200 nm. These results demonstrate the full fibrillar growth of htau40 and htau23
monomer on htau40 seeds.

This lack of cross-seeding barrier on full-length 4R seeds showed a deviation
from the trend observed in similar experiments using truncated 4R seeds (88,
131). To ensure experimental conditions that were changed from previous
studies were not responsible for the difference in growth properties, these
changes were applied to experiments with the full-length 4R seeds. The first
difference was the temperature at which nucleation of monomeric htau40 took
place, allowing initial seed fibrils to form at 25 °C rather than 37 °C. Once formed,
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growth experiments were carried out in the same manner and no growth barrier
was observed (Figure 3.3 A). Another difference was the mutation of the two
native cysteines into serines for previous truncated experiments, so the same
mutations were made to the full-length 4R to make it a cysteine free or cysless
(htau40 CL) construct. Growth patterns for htau40 CL seeds also show no growth
barrier (Figure 3.3 B). Finally, a combination of the two changes, nucleating the
cysless construct at 25 °C, also resulted in fibrils with no growth barrier (Figure
3.3 C). Therefore, the additional residues present from the N- and C-terminal
ends of the htau40 variant are likely responsible for this change in growth barrier.

Figure 3.3 Growth properties of htau40 fibrils with various nucleation
temperatures and/or native cysteine content. Representative gel and box-andwhisker plot showing quantification of fibril growth for reactions between htau40 seeds
formed at 25 °C (A), htau40 CL (native cysteines replaced by serines) seeds formed at
37 °C (B), and htau40 CL seeds formed at 25 °C (C). P = pellet, S = supernatant, n =
number of biological replicates. These findings show that changing the native cysteines
in htau40 to serines and/or the nucleation temperature does not affect the ability of its
seeds to recruit htau23 monomers.
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3.3

Seeding properties of N- or C-terminally truncated tau
Growth properties of different truncated variants were used to investigate

the impact regions of the N- and C- terminus have on the conformation fibrils
assume during their nucleation. These variants differ by truncations made at
either the N- or C- terminus, or both (Figure 3.4).

Figure 3.4 Schematic diagram of truncated variants used for growth studies. Nterminal inserts are striped, repeats are shaded. Numbers represent the amino acids
contained in each variant, numbering with respect to htau40.

The first two variants to be investigated were those with truncations to only
the N-terminal end, containing amino acids 151-441 or 244-441 (numbering
scheme corresponding to htau40). When these variants were used as the
monomeric species during nucleation, and the resulting fibrils were sonicated
then offered full-length htau40 or htau23 monomers, no growth barriers were
observed (Figure 3.5 A, B). Similarly, when C-terminally truncated variants, 1-421
56

and 1-391, were subjected to the same fibril formation, fragmentation, and
seeded reaction conditions; they also showed no observable growth barriers
(Figure 3.5 C, D). The 1-372 variant, while showing no barrier with htau40
monomers, did however show a significant growth barrier to full-length htau23
monomers (Figure 3.5 E). This suggests that the C-terminal end affects tau
conformation and seeding competency.

Figure 3.5 Seeding properties of fibrils composed of N- or C- terminally truncated
variants. Fibrils used for seeding were formed from 5 different N- or C- terminally
truncated htau40 variants, 10% of these seeds were offered to htau40 or htau23
monomers and let quiescently incubate for 20-24 hours at 37 °C. A-E, a representative
gel with Coomassie staining of growth reactions with each seed type, along with a boxand-whisker plot depicting quantified results for multiple reactions. P = pellet, S =
supernatant, n = number of biological replicates, statistical analysis was done using a
paired t-test ****, p≤ 0.0001. Htau40 monomers were fully recruited to all seed types,
and only the 1-372 variant produced fibrils with a partial htau23 growth barrier.
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3.4

Seeding properties of N- and C-terminally truncated tau
To investigate the impact the C-terminus has on fibril conformation, and

potential synergism between the N- and C-terminal regions, the growth
properties of variants with truncations to both the N- and C-terminus were
investigated. Variants all began at residue 244, the beginning of the first MTBR,
and varied in the number of amino acids remaining on the C-terminal end
extending to residue 421, 391, 384, 378, 372 or ending immediately at the end of
the fourth repeat at residue 368 (Figure 3.4). The growth properties of seeds
made up of these different variants was assessed in a manner similar to other
growth reactions thus far, looking at their ability to recruit both htau40 and htau23
monomers. All seeds were able to recruit htau40 monomers, but the ability to
recruit htau23 successfully diminished in correlation with systematic truncation to
the C-terminal end (Figure 3.6 A-F). The mean percent of 3R growth on these
variants started at 88% for the 244-421 variant dropping to 79%, 66%, 52%,
36%, and finally 26% for the 244-368 variant. These results suggest that the Cterminal residues of htau40 play a role in influencing the conformation of fulllength 4R tau fibrils, and residues on the N-terminal end seem to play a
synergistic role. The synergism of the N-terminal residues is suggested by results
showing variants with only small C-terminal truncations were fully able to recruit
htau23, but when that same C-terminal truncation was combined with a Nterminal truncation, partial growth barriers were observed (compare Figure 3.5 C,
D to Figure 3.6 A, B).
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Figure 3.6 Seeding properties of fibrils composed of N- and C- terminally
truncated variants. Fibrils used for seeding were formed from 6 different truncated
htau40 variants that all have had residues N-terminal to the repeat regions removed and
a systematically shorted C-terminus. 10% molar equivalent seeds were offered to htau40
or htau23 monomers and let quiescently incubate for 20-24 hours at 37 °C. A
representative gel of these growth reactions with each seed type, along with a box-andwhisker plot depicting quantified results for multiple reactions are shown in A-F. P =
pellet, S = supernatant, n = number of biological replicates, statistical analysis was done
using a paired t-test ** , p ≤ 0.01, **** , p ≤ 0.0001. These results show that all variants
are able to fully recruit htau40 monomers, and that the successive shortening of the Cterminus results in an increased growth barrier of htau23 monomers.

3.5

Seeding properties of P301S and P301L fibrils
In addition to truncations it was of particular interest to investigate the

impact specific point mutations have on fibril growth properties, as number of
familial mutations have been associated with 4R or 3R tauopathies (65). Some
mutations cause an increase in splicing, resulting in the overexpression of either
4R or 3R variants. However, there are some mutations that have been shown to
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not change the 4R/3R ratio, yet still present with preferential deposition of 4R or
3R in affected brain regions (24). The protocol exploring growth via
conformational templating of monomer onto preformed seeds allows for
investigation of whether fibril conformers formed from mutant tau exhibit growth
properties that align with the pathology of the mutant in vivo. Mutations of the
proline at position 301 to either a serine or a leucine, referred to as P301S or
P301L, are associated with 4R tauopathies but have been documented to cause
little to no change in the 4R/3R ratio (135). These mutations were introduced into
the htau40 construct. Seeds formed from the respective mutant monomers were
then subjected to the same growth analysis as previously described. Both P301S
and P301L mutant seeds were able to recruit non-mutant htau40 monomers, but
both showed a very robust seeding barrier for htau23 monomers (Figure 3.7 A, B
left and middle panels). It is interesting to note that while mutant seeds did recruit
htau40 monomers, this heterotypic recruitment was slower with T ½ = 60-68 min
(Figure 3.7 A, B right panels), than the growth rate of homotypic htau40
monomers on htau40 seeds (T ½ = 25-27 min) (Figure 3.2 C). It is also
significantly slower than the homotypic mutant monomers on mutant seed
growth, displaying full recruitment with a T ½ = 5-9 min (Figure 3.7 C-F). This
significantly slower heterotypic growth rate is in agreement with the previously
observed preferential growth of mutant over non-mutant 4R tau (135). The
aggregation seen here between mutant seeds and either htau40 monomers or
mutant monomers is fibrillar in nature as evidenced by TEM images of this
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growth. TEM additionally confirms the lack of fibril growth when htau23
monomers are offered to these same mutant seeds (Figure 3.8 A, B).
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Figure 3.7 Seeding properties of P301S and P301L fibrils. A and B, representative
gel, densitometric quantification represented as box-and-whisker plot, and ThT kinetics
of heterotypic growth reactions between htau40 (blue traces) or htau23 monomers (red
traces) with P301S and P301L mutant seeds respectively. C and D, representative gel
and box-and-whisker plot depicting quantified results from homotypic P301 mutant
seeding reactions. E and F, ThT kinetics of mutant homotypic growth reactions (green
and blue traces), along with seed controls (red traces). P = pellet, S = supernatant, n =
number of biological replicates, statistical analysis via paired t-test ****, p ≤ 0.0001, error
bars represent means ± S.D. from 4 measurements. These results indicate both P301S
and P301L fibrils are able to recruit htau40 monomers and their respective mutant
monomers, but are unable to efficiently recruit htau23 monomers.
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Figure 3.8 TEM analysis of P301S and P301L seeded reactions. Growth resulting
from htau40 monomers (left panel), htau23 monomers (middle panel), or P301 mutant
monomers (right panel) offered to mutant seeds. A, P301S seeded reactions. B, P301L
seeded reactions. Scale bars on all images are 200 nm. These results indicate mutant
P301 seeds with htau40 monomers or mutant monomers result in fibrillar growth, and
confirms the inability of htau23 monomers to be recruited to either type of mutant seed.

3.6

Mutant fibrils without observable growth barriers
The significant seeding barrier of 3R tau monomers seen with P301 mutant

fibrils led to question whether any variant with a point mutation in in this region
would form fibrils with a 3R growth barrier, or if this growth phenomenon was
particular to mutating this specific residue. In order to investigate this, six new
mutant variants were created, again using htau40 as a template. These variants
include three familial mutations, ΔN296, G303V, and S305N, also known to be
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associated with 4R tauopathies (24). These mutants were subjected to the same
fibril formation, fragmentation, and seeded reaction conditions as previously
described. These mutant seeds were all able to fully recruit both htau40 and
htau23 monomer, with the only exception being a slight htau23 barrier seen with
ΔN296 seeds (Figure 3.9 A-C).
The three other mutant variants investigated were V306D, I308D and Y310D.
These were chosen not because they were familial mutants, but because they
reside in the PHF6 motif from residues 306-311. This motif has been identified as
an important element for tau fibril aggregation (136). The anticipation was that a
mutation to any of these natively hydrophobic amino acids into a negatively
charged aspartic acid might cause a disruption of β-sheet packing and potentially
alter fibril conformation. However, if the mutation did alter fibril conformation it
was not in such a way as to cause preferential recruitment. Fibrils comprised of
these mutants were able to nucleate under stirring conditions, and fully recruit
both htau40 and htau23 monomers (Figure 3.9 D-F). Combined with the P301
mutant data, the lack of strong growth barriers for these six fibrils with mutations
in close proximity to position 301 suggests the proline at position 301 plays a
unique role in determining fibril structure.
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Figure 3.9 Seeding properties of fibrils with mutations flanking position 301.
Representative gel and densitometric quantification represented as box-and-whisker plot
for 10% seeded growth reactions between various mutant seeds with htau40 or htau23
monomers. A-C, results from reactions initiated from familial mutant composed seeds,
ΔN296, G303V and S305N, respectively. D-F, results from reactions initiated from
synthetic PHF6 motif mutant composed seeds, V306D, I308D, and Y310D respectively.
P = pellet, S = supernatant, n = number of biological replicates, statistical analysis via
paired t-test *, p≤ 0.05. These results identify no htau40 or htau23 growth barrier for any
mutant seed type, with the exception of a minor htau23 growth barrier on ΔN296 seeds.

3.7

CW EPR of htau40, P301 mutant, and K18 seeded fibrils
The 3R growth barriers seen with some truncated and P301 fibrils, but not

with htau40 fibrils, is likely due to structural differences in the core of these fibrils.
To investigate whether or not certain residues reside in the core of different fibril
types, site-directed spin labeling in conjunction with electron paramagnetic
resonance (SDSL-EPR) experiments were performed. Continuous wave (CW)
EPR was used due to its success gaining insight on side-chain stacking and
65

structural rigidity of tau protein in previous experiments (89, 125). Seven different
reporter monomers were made to probe whether certain residues were part of
the core of htau40, P301S, P301L, and K18 fibrils. These monomers had the
native cysteines replaced with serines (shown to not affect growth barriers Figure
3.3), and a single cysteine introduced at one of the following residues, 342, 343,
345, 360, 369, 371 or 375. Mutants were made in the 4R construct because it
was fully recruited onto all seed types. These mutant monomers were labeled
with either paramagnetic nitroxide label MTSL or its nonparamagnetic analogue.
Once attached, these paramagnetic and nonparamagnetic moieties are referred
to as R1 and R1’ respectively. The purity of these labeled monomers was
confirmed before usage by SDS-PAGE with Coomassie staining (Figure 3.10 A).
R1 proteins all diluted to 10 µM produced EPR spectra with similar signal
intensity, suggesting a similar labeling efficiency. These spectra also exhibited
three sharp lines with 34 G separation between outer peaks, as expected for a
spin labeled intrinsically disordered protein (Figure 3.10 B) (133).

66

Figure 3.10 Site-directed spin labeling and CW EPR analysis of htau40 single
cysteine mutant monomers. A, equivalent concentrations of seven single cysteine tau
monomers with paramagnetic label (R1) or nonparamagnetic label (R1’) visualized on
SDS-PAGE with Coomassie staining. B, CW EPR spectra of 10 µM R1 monomer
collected at X-band with 150 G sweep width, 1 G modulation amplitude, and 12 mW
incident microwave power. Axes are the same for all spectra. This data confirms the
purity and intrinsic disorder of these labeled monomers.

Once the quality of monomers was confirmed they were used in seeded
reactions with htau40, P301S, P301L, or K18 (244-372) seeds. These seeds
were chosen because we wanted to investigate regions of structure in htau40
fibrils in comparison to fibrils that exhibited a 3R growth barrier. Following
incubation, the growth reactions were centrifuged at 128,000 x g for 30 min.
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Pelleted fibrils were resuspended in 15 µL assembly buffer in order to transfer
them into capillary tubes appropriate for EPR measurements. Fibril spectra with
depressed amplitudes and single-line characteristic indicate a high amount of
spin exchange is occurring. This increased spin exchange is due to the R1
moiety being in a region of high structural order, where they are stacked on top of
one another. Alternatively, spectra exhibiting three sharp lines with increased
amplitude suggests the labeled residue is in a region of more disorder (125). All
seeded fibrils with label attached at positions 342, 343, and 345 produced
spectra with single-line characteristics. This suggests that for all seed types,
(htau40, P301S, P301L and K18) these residues likely reside in the structured
fibril core comprised of parallel in-register β-strands (Figure 3.11 A). When
monomer labeled at the remaining positions, 360, 369, 371 and 375 were grown
onto htau40 seeds, the resulting fibrils also produced spectra with single-line
characteristics. These spectra contain less than 2% contribution from mobile
components as determined by spectral subtraction. Again, the lack of hyperfine
structure in these spectra can be attributed to spin exchange between contacting
labels since they are repeatedly stacked on top of one another along the fibril
axis (75). However, when monomer labeled at positions 360, 369, 371 and 375
were grown onto fibrils that have a 3R tau growth barrier (P301S, P301L and
K18), they revealed spectra dominated by three sharp lines. This spectral
characteristic suggests these residues are in a less structured region, a striking
difference from htau40 fibrils (Figure 3.11 A). The labeled monomer is still
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incorporated into these fibrils, and as such does exhibit decreased mobility and
some spin exchange component in comparison to labeled monomer that is not
incorporated into a fibril. The label simply resides in a region of structural
disorder rather than the ordered core region, and do not experience as much
spin exchange as core labeled residues do. These spin exchange characteristics
are consistent with spectra previously published where residues in the first and
second repeat were labeled in the htau40 fibrils (125). Spectra to be compared
were normalized to the same number of spins using double integration. Once
normalized, spectral amplitude is one way to quantify and compare label mobility
for different monomers grown on different seed types. A plot of these amplitudes
for the spectra discussed above highlights the structural difference in htau40
fibrils which recruit both 4R and 3R, to those which do not recruit 3R (Figure 3.11
B).
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Figure 3.11 EPR analysis of MTSL labeled monomer grown onto htau40, P301S,
P301L, and K18 seeds. Single cysteine mutant monomers labeled with paramagnetic
spin label were offered to four different seed types, the resulting fibrils were pelleted and
analyzed using CW EPR. A, spectra normalized to the same number of spins for all
reaction combinations where the top horizontal row indicates the position of the R1
moiety in the monomer, and the leftmost vertical column indicates the type of seed used
to initiate growth. Spectra were collected at X-band with 150 G scan width, 3 G
modulation amplitude, and 12 mW incident power at room temperature. B, plot of signal
amplitudes from biological triplicate measurements showing mean + S.D. This data
highlights the difference in residues residing in the core of htau40 fibrils from those of
P301S, P301L and K18 fibrils.

70

Many of the spectra for the growth reactions described above were
dominated by spin exchange because 100% of the monomer used for the
reactions was paramagnetically labeled. To gain information more specifically
about label mobility, spectra absent of this complete spin exchange must be
obtained. To do this, a dilution of the spins was done where reactions were set
up with the same seed types, but used a 1:4 molar ratio of paramagnetic to
nonparamagnetic labeled monomer respectively. The spectra from such growth
reactions revealed the same overall spectral trend. All mutants grown onto
htau40 seeds exhibited a broadened three-line spectrum with a 68 G outer peak
separation, characteristic of immobilized spin labels (75). Monomer with labeled
positions 342, 343, and 345 grown onto P301S, P301L and K18 seeds also
shared this spectral characteristic (Figure 3.12 A). But on these three seed types,
monomer labeled at the positions in the end of the fourth repeat or just outside
the fourth repeat indicated higher side-chain mobility (75). These spectra have
some immobile components, but are dominated by three sharp and narrow peaks
with a 34 G outer peak separation. Again, a plot of signal amplitudes highlights
the trend of different regions of structural order in the htau40 fibrils compared to
P301S, P301L and K18 fibrils (Figure 3.12 B).
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Figure 3.12 EPR analysis of fibrils containing a mixture of paramagnetically and
nonparmagnetically labeled monomer. Four different seed types were offered single
cysteine mutant monomers with paramagnetic and nonparamagnetic labels (R1 and R1’)
in a 1:4 molar ratio respectively, the resulting fibrils were pelleted and analyzed using
CW EPR. A, spectra normalized to the same number of spins for all reaction
combinations where the top horizontal row indicates the position of the R1 and R1’
moiety in the monomer, and the leftmost vertical column indicates the type of seed used
to initiate growth. Spectra were collected at room temperature at X-band with 150 G
scan width, 3 G modulation amplitude, and 12 mW incident power. B, plot of signal
amplitudes from biological triplicate measurements showing mean + S.D. This data
highlights the difference in core structure of htau40 fibrils from P301S, P301L and K18
fibrils.
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3.8

DEER analysis reveals distinct ensembles of fibril conformers
Experiments thus far have highlighted the different growth properties and

different residues in the core of htau40 and P301 mutant fibrils. But identifying
whether or not these growth reactions contain a mixture of fibril conformers or
are defined by a single conformer remained a question. To address this question
another type of EPR, DEER, was used. This technique allows for the
measurement of distances between a pair of spin labels (137). Two spin labels
were introduced within the same monomer type and a dilute percentage of this
doubly spin labeled monomer was used in growth reactions. The distance
distribution from a DEER measurement of all fibrils in a reaction mixture can
identify whether or not multiple conformers exist. If only one conformer is present
the distance between the labeled residues will be the same and only one peak
will arise in the analysis. However, if multiple conformers exist within a single
reaction, multiple peaks will be seen on spectral analysis as each different
conformer will have a different distance between spin labels. This technique has
been successfully used in previous studies to probe fibril structure and
distinguish different fibril conformers (76).
The label positions used for these experiments were 311/328, as they were
previously successful in structural studies of truncated tau protein (K18) (64).
Three different monomeric versions, all in the htau40 template, of spin labeled
monomer were used. Monomer to be grown on htau40 seeds had the native
cysteines replaced by serines, and two cysteines introduced at the labeling
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positions. Monomer to be grown on P301S or P301L seeds additionally had the
mutation that their respective seed also contained. Successful MTSL labeling of
these monomers was confirmed using CW EPR, where spectra showed three
sharp lines as expected for label attached to a monomeric intrinsically disordered
protein (133) (Figure 3.13 A-C top panels). Fibrils were grown by combining
these labeled monomers with 25-fold molar excess of non-labeled monomer,
10% seed, and heparin then let incubate before being pelleted as previously
described. Pelleted fibrils were resuspended in 15 µL assembly buffer and
loaded into EPR tubes. The large dilution of labeled monomer was done to
ensure that any detected distances were between spin labels on the same
monomer, and not intermolecular distances between different monomers. CW
EPR spectra of these fibrils were collected before being flash frozen and
subjected to DEER measurements. Broadened three-line spectra with depressed
amplitudes suggest label immobility indicating the paramagnetically labeled
monomers have been incorporated into the fibril, and are not preferentially
stacked on one another, but rather distributed along the long fibril axis (Figure
3.13 A-C bottom panels). If labeled monomers were preferentially stacked
together, they would have experienced spin exchange, and the resulting spectra
would have exhibited single line characteristics.
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Figure 3.13 CW EPR analysis of spin labeled monomer and fibrils used for DEER
measurements. CW EPR spectra collected at X-band with 150 G sweep width and 12
mW incident power. Spectra on the top and bottom row used 1 G or 3 G modulation
amplitude respectively. A-C top row, representative CW spectra for the same
concentration of htau40, P301S, P301L monomer doubly MTSL spin labeled at positions
311 and 328. Axes are the same and the similar sharp three-line spectra with 34 G peak
separation indicate the similar labeling efficiency of the three monomer types. A-C
bottom row, representative CW EPR spectra of fibrils to be further analyzed using
DEER. Spectra collectively reveal that spin labeled monomers were incorporated into
fibrils and distributed along the fibril axis as they show an immobile component (arrows
indicating 68 G separated outer peaks), but are not dominated by spin exchange.

Triplicate DEER data was collected for each different seed type and a
representative dipolar evolution curve with corresponding distance distributions
after Tikhonov regularization are shown in (Figure 3.14 A, B). The steeper initial
drop in the dipolar evolution curve from htau40 fibrils as compared to both P301S
and P301L fibrils agrees with shorter distance peaks in their distributions (Figure
3.14 left vs middle and right panels). The lack of multiple strong dipolar
oscillations in the evolution curves is consistent with bi-labeled molecules with
broad distance distributions like those shown here (138). This data indicates that
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all three types of fibrils are ensembles (clouds) of conformers, and that the
ensemble of htau40 fibrils is different from that of P301S and P301L fibrils.

Figure 3.14 DEER analysis of fibrils seeded with htau40, P301S, or P301L. All data
analyzed using Tikhonov regularization. Left panels, htau40-seeded fibrils. Middle
panels, P301S-seeded fibrils. Right panels, P301L-seeded fibrils. A, representative
background corrected dipolar evolution curves in the time domain shown as black traces
with best fits in red. B, distance distributions, different shaded traces represent biological
triplicates for each different fibril type. The data shows that all fibrils are ensembles of
conformers, and that the htau40 fibril ensemble is distinct from those of P301S and
P301L fibrils.

76

CHAPTER FOUR: OXIDATION OF FOUR-REPEAT TAU RESULTS IN
UNIQUE FIBRIL PROPERTIES

4.1

Implications of htau40 oxidation on fibril structure
Identification that truncations and specific point mutations promote the

formation of distinct fibril conformers raised the question whether changes in
reaction conditions could have a similar result. Oxidation of tau protein is a
condition of interest because brain tissue is particularly vulnerable to oxidative
stress given its high oxygen consumption and high metabolic rate (47).
Additionally, neurodegenerative disease pathology correlates to increased
exposure to oxidative conditions (139). Increased oxidative damage has also
been identified in early disease stages meaning its effects have the potential to
influence initial fibril formation (140). Due to the presence of two native cysteines
in htau40 at positions 291 and 322, under oxidizing conditions, the formation of a
disulfide bond between these residues is possible. This disulfide bond could
affect the preferred monomer fold, thus impacting fibril core structure and growth
properties. Previous studies have highlighted how intermolecular disulfide bonds
form species which readily promote aggregation (56). This is consistent with the
NDP growth model for tau fibril formation, as the bringing together of monomers
with a disulfide bond would decrease the energetic barrier of nucleation, which is
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typically the rate limiting step in fibril formation (90). These intermolecular
species however are not the subject of the experiments herein. My interest lies in
the growth properties of intramolecularly disulfide bonded htau40 monomers. It
has been proposed that monomers with an intramolecular disulfide bond can
influence fibril structure (57), but a thorough characterization of these fibrils and
their growth properties is lacking.

4.2

Isolation of intramolecularly disulfide bonded htau40 monomer
In order to study the growth properties of fibrils comprised of monomers

that possess an intramolecular disulfide bond, these monomers first need to be
isolated from species that possess intermolecular disulfide bonds. Oxidation
reactions took place by combining freshly monomerized htau40 with hydrogen
peroxide. After allowing this reaction to incubate at 25 °C for 16-20 hours the
hydrogen peroxide was dialyzed out and the reaction was spin concentrated
down to 1.5-2 mL. In order to separate any higher order species (dimers, trimers,
etc) from monomers, a 0.5 mL fraction size was utilized on a superdex 200
10/300 GL size exclusion column. The higher order species begin to elute off the
column at approximately 10 mL and are represented by the small peak seen as a
left shoulder of the large absorption peak (Figure 4.1 A, C). In order to correctly
pool fractions containing only monomer, the fractions containing elution volume
9-16 mL were run on SDS-PAGE gels using SDS sample buffer that did not
contain any reducing agent. Reducing agent is present in typical sample buffer
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so with the combination of the SDS in the gel and the reducing agent in the
buffer, all proteins running on the gel will be denatured and no disulfide bonds
will be present. However, since the only way the monomers in question can be
differentiated from higher order species are disulfide bonds, it is critical that they
not be broken. Using this method, fractions containing only monomer were able
to be differentiated from those with some higher order species, and these
fractions (elution volume 13-14.5 mL) were then pooled for experimental use
(Figure 4.1 B). The formation of more intramolecular disulfide bonds rather than
intermolecular bonds in the sample was promoted by optimizing the
concentration of monomer to be 20 µM htau40 with 5 mM H2O2 in the initial
oxidation reaction. When a higher monomer concentration (100 µM htau40) is
used an increased percentage of higher order species can be seen (Figure 4.1
C, D) and therefore less monomer can be recovered for further experimental use.
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Figure 4.1 Isolation of intramolecularly disulfide bonded htau40 monomer.
Following oxidation of htau40 monomer with hydrogen peroxide, reactions were sent
over a superdex 200 gel filtration column. Fractions (0.5 mL) were collected and those
corresponding to the absorbance peak were analyzed using SDS-PAGE with no
reducing agent present in the SDS sample buffer. A and B, show the absorbance peak
profile and corresponding gel from an oxidation reaction with 20 µM htau40 and 5 mM
hydrogen peroxide. C and D, show the absorbance peak profile and corresponding gel
from an oxidation reaction with 100 µM htau40 and 5 mM hydrogen peroxide. Different
total reaction volumes were used. These data highlight that optimization of htau40 to
hydrogen peroxide concentration allows for the promotion of intra over intermolecular
disulfide bond formation, and the ability to isolate this intramolecular disulfide bonded
monomer.

Verification that oxidation had in fact occurred, and the monomeric
species recovered from gel filtration did possess an intramolecular disulfide
bond, was done using CW EPR. Due to the fact that the spin label MTSL
attaches to a cysteine residue, in monomers that possess a disulfide bond
between its two cysteine residues no label should be able to attach. This would
be represented by a lack of signal in their spectrum following an MTSL labeling
protocol. A control utilizing htau40 monomer that has not been oxidized (free
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cysteines) is shown in Figure 4.2 A. The three sharp lines in this spectrum are
indicative of high spin label mobility, as expected when attached to intrinsically
disordered proteins like monomeric tau (133, 141). In comparison, htau40
oxidized monomer (collected from the protocol discussed above) that was
subjected to the same labeling protocol shows negligible signal (Figure 4.2 B),
indicating that the cysteines are not free. If the bond blocking these cysteines
from being MTSL labeled is a disulfide it should be reversible in nature. To test
this, monomer collected from gel filtration following the oxidation protocol was
treated with DTT, dialyzed to remove the reducing agent, then subjected to the
MTSL labeling protocol. The spectrum from this monomer now does show MTSL
signal (Figure 4.2 C). Collectively these data suggest that monomeric
intramolecularly disulfide bonded htau40 has been isolated, and I will refer to it
as htau40 oxidized.

Figure 4.2 Verification of disulfide bond in monomeric species. Three different
types of monomer were subjected to MTSL labeling protocol followed by CW EPR to
assess labeling efficiency. All samples were 5 µM. A, htau40 freshly monomerized not
subjected to oxidation reaction. B, htau40 oxidized monomer following oxidation
protocol. C, htau40 oxidized monomer following oxidation protocol then treated with
reducing agent. Spectra were collected at room temperature at X-band with 150 G scan
width, 1 G modulation amplitude, and 12 mW incident power. Same axes used for all
plots. These results suggest that the monomer collected following the oxidation protocol
is intramolecularly disulfide bonded.
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4.3

Htau40 oxidized monomer forms fibrils competent to seed homotypic
growth
It was necessary to first form oxidized fibrils before their growth barriers

could be assessed. This was done in a similar manner as described in the
previous chapter, by combining htau40 oxidized monomer with heparin and
allowing it to aggregate following the nucleation and elongation scheme for 7-8
days at 37 °C under agitating conditions. Due to some discrepancies in the field
whether intramolecularly disulfide bonded monomer form fibrils (57, 142) or not
(56), the fibrillar nature of this initial growth was confirmed using TEM (Figure 4.3
A). Once fibrillar nature was confirmed it was of interest to also show these fibrils,
when subjected to a harsh sonication, fragment in such a way that it is practical
to use them as seeds to initiate fibril growth as shown in the previous chapter.
Under harsh sonication conditions these oxidized fibrils do fracture in a fairly
uniform manner into shorter fibril fragments with an average length of 42 nm
(Figure 4.3 B, C). The seeding competency of these fibrils was first tested in
homotypic growth reactions utilizing 10% molar monomer equivalent seed. These
reactions result in protein exclusively being found in the pellet fraction (Figure 4.3
D). This growth trend is reproducible as it was observed for >15 biological
replicates (Figure 4.3 E). Seeded growth of oxidized monomers was also
demonstrated using ThT fluorescence (Figure 4.3 F). Importantly the
experiments suggest that this aggregation is not spontaneous monomer
nucleation. This is evidenced by the lack of a lag phase and lack of signal
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intensity increase from monomer controls in the absence of seeds. TEM was
again used to highlight that the assembled structures from these seeded
reactions are fibrillar (Figure 4.3 G). Collectively, these results suggest that fibrils
form from intramolecularly disulfide bonded htau40 monomers, and that those
fibrils are competent to recruit other htau40 oxidized monomers.

Figure 4.3 Fibril formation of htau40 oxidized monomers and homotypic growth. A
and B, TEM image of fibrils formed from htau40 oxidized monomer before (A) and after
(B) sonication. Scale bars = 100 nm. C, distribution of htau40 oxidized seed lengths. D
and E, representative gel and scatter plot displaying results from quantified 10% seeded
homotypic htau40 oxidized (Ox) growth reactions. P = pellet, S = supernatant, n =
number of biological replicates. F, ThT fluorescence showing kinetics of a homotypic
htau40 Ox seeded reaction (red trace), seed control in the absence of monomer (blue
trace), and monomer control in the absence of seed (green trace). Error bars represent ±
S.D. from triplicate measurements. G, TEM image of fibrils resulting from a homotypic
htau40 Ox seeded reaction. Scale bar = 100 nm. The results demonstrate the ability of
htau40 oxidized monomers to form fibrils that can seed homotypic fibrillar growth.
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4.4

Specific recruitment properties of oxidized fibrils
It was observed that oxidized monomers grew on htau40 oxidized seeds

in homotypic reactions. Next, the recruitment of other monomeric species in
heterotypic reactions was examined. The monomers chosen to probe this
question were two different variants of htau40 cysless, where the native
cysteines have been replaced with serines (htau40 SS) or alanines (htau40 AA),
and htau23 containing only one native cysteine at position 322. The lack of an
increase in ThT fluorescence when these monomers are offered to htau40
oxidized seeds indicates the inability of these monomer types to elongate
oxidized seeds (Figure 4.4 A). This seed type is not simply incompetent for all
seeding reactions, just with these particular monomers. As highlighted in the
previous section (Figure 4.3 D-G), and by the control trace showing oxidized
monomer on oxidized seed growth (Figure 4.4 A red trace). Sedimentation
reactions offering 10% oxidized seed to cysless and htau23 monomers also
show a significant growth barrier as the protein is seen entirely in the supernatant
following a 20-24 hour incubation period, high speed centrifugation, and SDSPAGE assessment (Figure 4.4 B). This growth barrier is reproducible, as different
biological replicates showed an average of 12%, 6% and 5% growth for all three
monomer types, htau40 SS, htau40 AA, and htau23 respectively (Figure 4.4 C).
This growth barrier is in contrast to the growth observed when htau40 SS, htau40
AA, or htau23 monomers are offered to htau40 reduced seeds. For purposes of
comparison I will refer to htau40 fibrils formed in the presence of reducing agent,
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like those discussed in the previous chapter, as htau40 reduced fibrils. These
htau40 reduced fibrils show no growth barrier or diminished recruitment
properties towards htau40 SS, htau40 AA, or htau23 monomer. This is shown by
ThT fluorescence kinetics where all three monomer types, along with htau40
reduced monomer as a control, show an increase in fluorescence intensity
(Figure 4.4 D). Growth efficiency was also determined by sedimentation
reactions using the 10% (molar equivalent) seeded protocol. Protein is seen
entirely in the pellet fractions when using reduced seeds rather than oxidized
seeds (Figure 4.4 E). This trend is reproducibly seen for multiple biological
replicates, displaying 95%, 95% and 98% growth of all monomer types (htau40
SS, htau40 AA, htau23 respectively) (Figure 4.4 F).

85

Figure 4.4 Growth barrier of htau40 SS, htau40 AA, and htau23 on htau40 oxidized
seeds. A-C, results from growth reactions utilizing htau40 oxidized (Ox) seeds. D-F,
results from growth reactions utilizing htau40 reduced (Red) seeds. A and D, homotypic
growth reactions on either Ox or Red seeds show full growth (red traces), while
reactions with htau40 SS, htau40 AA, and htau23 monomer (orange, green and blue
traces respectively) show no growth on htau40 Ox seeds (A) and full growth on htau40
Red seeds (D). Seed control for Ox and Red seeds shown in purple. Error bars
represent mean ± S.D. from triplicate measurements. B and C, representative gel and
scatter plot depicting quantified results from heterotypic seeding reactions on htau40 Ox
seeds, or (E and F) htau40 Red seeds. P = pellet, S = supernatant. The results highlight
the inability of monomers without intramolecular disulfide bonds to be recruited onto
htau40 oxidized seeds. Recruitment of these monomers only occurs on reduced seeds.
This suggests a structural difference between oxidized and reduced fibrils.

To investigate if a minor population of oxidized seed conformers exists
that could recruit cysless tau, experiments were performed where htau40 SS
monomers were offered to 50% (molar monomer equivalent) htau40 oxidized
seeds. These results showed negligible htau40 SS recruitment (average 8%)
onto oxidized seeds (Figure 4.5 A). Additionally, it is interesting to note that a
crosslinked version of htau40 monomer, with a bismaleimide crosslinker
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possessing an 8 Å spacer arm connecting the two cysteines, also showed
minimal growth on htau40 oxidized seeds (average 4%) (Figure 4.5 B).
Collectively, the results presented thus far suggest that monomer recruitment
onto oxidized seeds is dependent on the presence of an intramolecular disulfide
bond in the monomer, and that the compact spacing of the disulfide bond is
potentially important to fibril growth.

Figure 4.5 Increased seed percentage and htau40 crosslinked growth reactions.
Representative gel and scatter plot depicting quantified results from htau40 SS
monomer with 50% (rather than typical 10%) htau40 oxidized (Ox) seeds (A), and
crosslinked monomer with 10% htau40 Ox seeds (B). The lack of growth in these
reactions is additional evidence supporting the importance of the disulfide bond within
monomer for growth on htau40 oxidized seeds.

To further investigate the necessity of an intramolecular disulfide bonded
monomer to elongate oxidized seed fibrils, htau40 monomer that had not been
subjected to reducing agent or an oxidizing agent was used for seeding
reactions. Cysteine containing htau40 monomer combined with 10% oxidized
seed and heparin was allowed to incubate in at 37 °C for 20-24 hours. The
growth resulting from these reactions was highly variable for different batches of
monomer offered to different batches of seeds on different days (data not
shown). One factor which could contribute greatly to this variability is the amount
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of oxidation the monomer has undergone. Without a reducing agent present it is
likely that oxidation can occur to the monomer because of the presence of
dissolved oxygen (55). To test this, two parameters were explored, allowing or
not allowing monomer oxidation during reaction incubation. No TCEP was
included for these reactions. To allow for more oxidation the temperature of
incubation was decreased from 37 °C to 25 °C (ambient room conditions) for
reactions between freshly monomerized htau40 and oxidized seeds. These
reactions were covered with a filter instead of in a closed tube to allow oxygen
exchange, but prevent any particulate matter from entering. Quantifying the
amount of protein in the pellet fractions from such reactions revealed that the
average percentage of growth for these reactions was 40% (Figure 4.6 A). The
opposite regime, where htau40 monomer has no chance to oxidize, was explored
using an anaerobic chamber. Again, no TCEP was used for these reactions.
Inside the chamber htau40 was monomerized, reactions were set up, and
incubation (at 37 °C) took place, ensuring the monomer being used has no
chance to oxidize and form disulfide bonds. Quantified results from these
reactions show a significant growth barrier, average of only 8% growth, from
biological triplicate seeds (Figure 4.6 B). Parallel experiments for both the 25 °C
open tube and anaerobic conditions utilizing the same setup and monomer, but
offered 10% htau40 reduced seeds, both yielded an average of 93% growth
(Figure 4.6 A, B). Collectively, these results suggest that in order for monomer to
be recruited onto oxidized seeds it needs to be able to form an intramolecular
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disulfide bond. This highlights the structural significance of the intramolecular
disulfide bond to these htau40 oxidized fibrils.

Figure 4.6 The oxidation of htau40 monomer determines its recruitment onto
htau40 oxidized seeds. Reactions on htau40 oxidized (Ox) seeds or htau40 reduced
(Red) seeds all utilizing freshly monomerized htau40 monomer that had no reducing
agent or oxidizing agent present. A, representative gel and scatter plot depicting
quantified results from reactions incubated at 25 °C in the presence of ambient room
oxygen. B, representative gel and scatter plot depicting quantified results from reactions
where the htau40 monomer was prepared in an anaerobic chamber, and reactions were
also set up then incubated at 37 °C in an anaerobic chamber. P = pellet, S =
supernatant. Paired t-test for statistical comparison *, p < 0.013, ***, p < 0.0006. Control
reactions on htau40 reduced seeds for both scenarios reveal the monomer being used is
growth competent. The difference in growth under variant conditions on htau40 oxidized
seeds suggests that the recruitment of htau40 monomer onto oxidized seeds is
dependent on its ability to form an intramolecular disulfide bond.

4.5

Oxidized and reduced fibrils are structurally distinct
Different growth barriers seen for oxidized and reduced fibrils suggest they

are structurally distinct from one another, yet further evidence of these
differences was desired. Due to the inability of cysteine free monomer to grow on
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oxidized seeds, structural analysis through EPR experiments was not possible.
However, other biochemical assays were employed to highlight the structural
differences between oxidized and reduced fibrils. One technique used to
evaluate conformational stability of fibrils is a guanidine melt. Fibrils are exposed
to a specific concentration of denaturant and the amount of fibrils that remain can
be quantified. When done over a series of concentrations a denaturation profile
for a fibril type can be determined (143). A fibril’s susceptibility to denaturation is
dependent on what regions of the protein are exposed (144), therefore
structurally distinct fibrils made up of the same monomer type could display
different denaturation profiles. Homotypic growth reactions were set up for
htau40 reduced and oxidized fibrils. Following incubation, the resulting fibrils
were aliquoted and guanidine hydrochloride (GndHCl) was added such that total
volumes were identical, but final GdnHCl concentration varied from 0-1.5 M.
These mixtures were then incubated quiescently at 25 °C for one hour before
being subjected to high speed centrifugation. Following sedimentation, pellet
fractions were analyzed by SDS-PAGE with Coomassie staining to assess the
amount of protein which remained fibrillar after GdnHCl treatment (Figure 4.7 A).
Oxidized fibrils appear to be more susceptible to denaturation, showing an
average of 36% of original fibrillar content remaining after a 0.25 M GdnHCl
treatment. In comparison, reduced fibrils retain 80% of their fibrillar content upon
0.25 M GdnHCl treatment for the same time frame. The different denaturation
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profiles for reduced and wild type fibrils suggest a difference in their
conformational stability (Figure 4.7 B).

Figure 4.7 Structural analysis of reduced and oxidized fibrils using Guanidine
denaturation. Following homotypic growth for htau40 reduced and oxidized fibrils,
reactions were aliquoted and treated with varying concentrations of GdnHCl for 1 hour
before being sedimented and pellets analyzed. A, representative SDS-PAGE
assessment of pellets for reduced (Red, top gel segment) compared to oxidized (Ox,
bottom gel segment) reactions when exposed to the same treatment conditions. B,
densitometric quantification of results from biological triplicates of reduced fibrils (red
trace) and oxidized fibrils (blue trace) indicating the normalized amount of pelleted
protein after each GdnHCl concentration treatment. Error bars ± S.D. from triplicate
measurements. The different denaturation profiles for reduced and oxidized fibrils
suggest a difference in their conformational stability.

One distinguishing feature of amyloids is their protease resistant core (77).
Limited protease digestion has been employed as a technique to highlight how
fibrils composed of the same type of monomer can be structurally distinct (76).
This is possible because proteases have preferential cleavage sites, and if the
conformation or packing of the monomer making up the core of two fibrils is
different, different cleavage sites will be exposed resulting in different cleavage
products. The protease used for these experiments was proteinase K (PK), a
broad-spectrum serine protease that preferentially cleaves after hydrophobic
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amino acids (145). Reduced and oxidized fibrils were grown in homotypic
seeding reactions and then subjected to a final concentration of 60 nM PK and let
incubate at 25 °C for 30 min. Following incubation, they were treated with a
protease inhibitor and mixed with SDS sample buffer before being run on SDSPAGE with Coomassie staining to visualize cleavage products. Controls were
also performed where assembly buffer rather than PK was used. Representative
control fibrils treated with only buffer show no degradation. Importantly, there are
subtle differences in the cleavage products of PK treated reduced and oxidized
fibrils (Figure 4.8). These differences are reproducible as they are observed for
fibrils initiated from biological triplicate seed batches. The data suggest that
reduced and oxidized fibrils are structurally distinct from one another.

Figure 4.8 Limited protease digestion of reduced and oxidized fibrils. Following
reduced (Red) and oxidized (Ox) homotypic growth reactions fibrils were proteolyzed for
30 min at 25 °C with equal amounts of proteinase K (PK) before being analyzed by SDSPAGE and Coomassie staining. Representative control growth for each fibril type with no
PK treatment (none for Red and Ox lanes), and biological triplicates of Red and Ox fibrils
all treated with 60 nM PK. The different banding pattern of reduced vs oxidized fibrils
reveals different proteolytic sensitivities of the two fibrils, suggesting they are structurally
distinct from one another.
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One final characteristic that was explored to show reduced and oxidized
fibrils are structurally distinct was their fragility. If fibrils are structurally identical,
they should fracture to a similar extent when exposed to the same sonication
stress. The tip sonication, described for the fracture of initial nucleated fibrils to
create seeds, is quite harsh as evidenced by the small, fairly uniform fragment
products (Figure 3.1 B, C and Figure 4.3 B, C). This is too extreme of a breakage
event to expect detection of any fragility differences, instead a milder sonication
event was necessary. Following homotypic seeding reactions, 100 µL of reduced
or oxidized fibrils were subjected to a 30 second sonication event in a bath
sonicator utilizing only 5% power. The sonicated fibrils were then diluted to be
approximately 2 µM and loaded onto EM grids to observe their extent of fracture.
Nonsonicated reduced and oxidized fibrils appear similar (Figure 4.9 Left panels
of A, B). However, after being subjected to the same sonication event, oxidized
fibrils fragment to a greater and more uniform extent than reduced fibrils (Figure
4.9 Middle panels of A, B). Quantifying the lengths of these fibril fragments
revealed that oxidized fibrils fracture to an average length of 209 nm, and
reduced fibrils fracture to an average length of 531 nm (Figure 4.9 Right panels
of A, B). The higher number of measured oxidized fibrils was due to their shorter
nature. To make sure no bias was introduced measuring the reduced fibril
lengths, quantifications shown in the bar graph are an average from biological
triplicates imaged on 9 different grids from >30 images.
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Figure 4.9 Fragility of reduced and oxidized fibrils assessed using EM. Following
homotypic growth reactions reduced (Red) (A) and oxidized (Ox) (B) fibrils were
analyzed by EM before (left panels) and after (middle panels) 30 second bath sonication.
Unsonicated images 49,000 x direct magnification. Sonicated images 98,000 x direct
magnification. All scale bars = 200 nm. A and B right panels, length distributions for
sonicated Red and Ox fibrils, showing the average lengths when subjected to the same
sonication event are 531 nm and 209 nm respectively. This indicates that oxidized fibrils
are more fragile than reduced fibrils.

4.6

Partial dissociation of oxidized fibrils
Seeded reactions with htau40 oxidized seeds identified the intramolecular

disulfide bond in oxidized fibrils is an important factor dictating their growth
properties. This factor made it of interest to investigate whether or not the
persistence of these bonds was critical to the fibrils after they were formed.
Identical homotypic oxidized seeded reactions were set up to be monitored via
ThT fluorescence. No reducing agent was present in initial reaction setup. Once
traces leveled off (suggesting the excess pool of monomer had been depleted
and equilibrium had been reached) the run was paused and reactions were
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treated with buffer as a control, or TCEP to a final concentration of 3 mM, then
incubation continued for 17.5 hours. Following treatment, the diminished intensity
in the ThT trace of those reactions treated with reducing agent (red trace), as
compared to the control reaction’s intensity (green trace), suggests some
dissociation of the oxidized fibrils (Figure 4.10 A). Quantification of the
dissociation event was done using a similar reaction setup without the presence
of ThT. Triplicate homotypic oxidized seeding reactions were set up and let
incubate. After 5 hours of growth one reaction was sedimented, one was treated
with assembly buffer, and the final reaction was treated with TCEP to a final
concentration of 3 mM. The two reactions that received treatments were
incubated quiescently at 37 °C for another 16-20 hours before being sedimented.
Fibril content for all three reactions was visualized on SDS-PAGE as described
previously (Figure 4.10 B). Protein being exclusively in the pellet fraction for
reactions spun down at the 5-hour time point suggests the observed effect is not
a stalling of growth at the time of treatment. The protein in the pellet for the
reaction treated with buffer indicates the dissociation is not a consequence of the
treatment protocol. The dissociation seen with a 3 mM TCEP treatment is due to
the effect of the reducing agent acting on the disulfide bonds within oxidized
fibrils. Biological replicates show the reproducibility of this trend, with an average
of 53% protein remaining in the pellet following 3 mM TCEP treatment (Figure
4.10 C).

95

Figure 4.10 Dissociation of oxidized fibrils. Fibrils from identical homotypic htau40
oxidized seeded reactions were let form before being treated with buffer or reducing
agent, followed by continued incubation. A, reactions monitored by ThT fluorescence,
after 4.5 hours of growth monitoring was paused so buffer (green trace) or 3 mM TCEP
(red trace) could be added to reactions, after treatment monitoring was resumed for
another 17.5 hours. B and C, representative gel and scatter plot depicting quantified
results from reactions that were either spun down after 5 hours of incubation, or treated
with buffer or 3 mM TCEP after 5 hours of incubation, then allowed to incubate for
another 16-20 hours before being sedimented to be analyzed by SDS-PAGE. P = pellet,
S = supernatant, paired t-test for statistical comparison ****, p < 0.0001. The results
indicate that the addition of reducing agent causes an approximate 50% dissociation of
oxidized fibrils.

Fibril dissociation could be an important physiological event; so, the
species present as a result of diminished long fibril content was characterized. As
described in chapter 3 and shown in Figure 3.1 D, short fibril fragments, like
those used for seeding reactions, remain in the supernatant when spun at
128,000 x g. Therefore, in order to determine what species is dissociating from
these oxidized fibrils, whether it be small seeding competent fibril fragments or
monomers that are in the supernatant following reducing agent treatment and
sedimentation, another technique must be used. Following sedimentation,
supernatants from these treated reactions were subjected to size exclusion
chromatography. The elution profile for the supernatant of buffer and TCEP
treated oxidized fibrils, along with a monomer control can be seen in Figure 4.11
96

A. When supernatant from buffer treated oxidized fibrils was run over a superdex
200 10/300 GL size exclusion column the resulting elution profile showed one
fairly prominent peak with an average elution volume of 8 mL and a significantly
smaller peak between 12-13 mL. The supernatant from TCEP treated oxidized
fibrils revealed a peak overlapping the 8 mL retention peak seen in supernatant
of the buffer control, along with a major peak eluting between 11-13 mL. The
elution profile of reduced htau40 monomer reveals the species eluting off
between 11-13 mL to be the monomeric species. SDS-PAGE on elution volume
6-17 mL, with 1 mL fractions corresponding to different lanes, was done for each
run (Figure 4.11 B-D). The intensity of protein bands corresponding to the premonomer peak do not match the expectation given the area under their peak
when measuring absorbance at 280 nm. This exaggerated peak intensity can
most likely be attributed to a scattering effect of this higher order species.
Densitometric quantification of protein bands on gels from the supernatant of
TCEP treated fibrils, from 10 different samples, reveals that an average of 88%
of the total protein is monomeric despite the intensity of the peak at 8 mL elution
volume. To explore the elongation competency of the dissociated monomeric
species, following centrifugation the supernatant fraction from treated fibrils was
offered to htau40 reduced seeds. The reactions resulted in full growth (data not
shown), and indicate the competency of the dissociated species to be recruited
onto new htau40 reduced seeds.
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Figure 4.11 Monomeric htau40 accounts for the dissociation of oxidized fibrils.
Supernatants from htau40 oxidized treated fibrils following growth, treatment, incubation,
and sedimentation, (along with a monomer control) were run on gel filtration. Resulting
elution fractions were analyzed using SDS-PAGE with Coomassie staining. A, elution
profiles from the supernatant of fibrils treated with buffer (red trace) or with 3 mM TCEP
(blue trace), and htau40 monomer control (green trace). Elution volumes 6-17 mL (in 1
mL fractions) were analyzed on SDS-PAGE for buffer treated fibrils (B), 3 mM TCEP
treated fibrils (C), and htau40 monomer (D) gel filtration runs. This data reveals that the
majority of species accounting for the 50% reduction in oxidized fibril content is
monomeric.

Notice that in the presence of reducing agent, fibrils did not fully dissociate
(Figure 4.10). Additional experiments were performed to test whether this was
due to insufficient amount of reducing agent, or whether the ensemble of fibrils
contains conformers that are differentially affected by reducing agent. To probe
the maximum extent of dissociation, oxidized fibrils were again grown in
homotypic seeding reactions and treated, this time with a different reducing
agent. DTT rather than TCEP was used to investigate if a different reducing
agent produced the same effect. The DTT concentrations used to probe the
maximum extent of oxidized fibril dissociation were 20 mM, 50 mM, and 100 mM.
Reactions were carried out as described with TCEP treatment, where seeded
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reactions were grown for 5 hours, treated, then let incubate for another 16-20
hours before being sedimented and fibrillar content assessed using SDS-PAGE
with Coomassie staining. The 20 mM, 50 mM, and 100 mM DTT treatments
resulted in an average of 46%, 50%, and 45% of protein remaining in the pellet,
respectively. This trend was reproducible for multiple biological replicates (Figure
4.12 A and B). The results suggest that the oxidized fibril growth reactions, like
reduced fibrils, contain a heterogeneous ensemble of conformers with a
subpopulation resistant to dissociation.

Figure 4.12 Maximum extent of oxidized fibril dissociation. Identical homotypic
htau40 oxidized seeded reactions were grown for 5 hours before being treated with
various concentrations of DTT, followed by a 16-20 hour incubation, then sedimented for
analysis via SDS-PAGE with Coomassie staining. A, representative gel for reactions
treated with buffer or 20 mM, 50 mM, or 100 mM DTT. P = pellet, S = supernatant. B,
scatter plot depicting densitometric quantification of results from biological replicates.
Paired t-test for statistical comparison ****, p < 0.0001, ***, p ≤ 0.0005. These results
highlight an approximate 50% as the maximum extent these htau40 oxidized fibrils can
be dissociated, suggesting htau40 oxidized fibrils are an ensemble of conformers.

4.7

Oxidation of htau40 by copper (II)
Dyshomeostasis of metal ions has been associated with

neurodegenerative diseases and been suggested to even alter the pathology of
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some diseases, like AD (146). Previous studies have used Cu2+ ions as an
oxidizing agent (142). This raised the question whether fibrils nucleated in the
presence of copper would exhibit properties more like the oxidized or reduced
fibrils discussed here. To investigate this, Copper (II) chloride (CuCl2) was
included during initial fibril formation and the growth properties of the resulting
fibrils were then probed. Fibril nucleation took place over several days agitating
at 37 °C, using freshly monomerized htau40 that had not been treated with
reducing agent or hydrogen peroxide, 5 µM CuCl2, and the usual cofactor
heparin. These fibrils were not formed in anaerobic conditions. Fibrils nucleated
using these conditions exhibit the same growth characteristics as fibrils formed
from fully oxidized monomer. The seeds exhibit an average growth of 91% with
oxidized monomer, partial growth with htau40 freshly monomerized without
reducing agent (average 56%), and a significant growth barrier for monomers
unable to form an intramolecular disulfide bond (average growth for htau40 SS
5%, htau40 AA 3%, and htau23 1%). Reproducibility of these growth trends was
confirmed with biological triplicate measurements (Figure 4.13 A and B). ThT
kinetics also suggest the oxidized nature of these seeds by their rapid
fluorescence increase with oxidized monomers (red trace), slower fluorescence
increase with htau40 monomers in the absence of reducing agent (blue trace),
and lack of fluorescence increase for htau40 SS, htau40 AA or htau23 monomers
(Figure 4.13 C). The slow htau40 growth (blue trace) is ascribed to the slow
oxidation of those htau40 monomers, which are then able to be incorporated. It is
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also interesting to note, a control experiment utilizing htau40 SS nucleated in the
presence of CuCl2 does not exhibit a growth barrier with htau23 monomer. This
highlights the nature of copper’s action with htau40 is directly related to the
cysteines. These in vitro findings suggest that a physiological increase of Cu2+
ions could impact not only tau nucleation kinetics, but the fibril growth properties
through oxidation of the native cysteines.

Figure 4.13 Copper can act to oxidize htau40 during nucleation. A and B,
representative gel and scatter plot showing densiometric quantification of reactions
carried out using seeds that had 5 µM CuCl2 added to provide Cu2+ ions during initial
fibril formation with htau40 monomer. Paired t-test for statistical comparison **, p =
0.0066, ***, p ≤ 0.0004. C, ThT kinetics showing the results of htau40 oxidized (Ox) (red
trace), htau40 (no reducing agent) (blue trace), htau40 SS (grey trace), htau40 AA
(green trace), or htau23 (orange trace) monomer offered to the htau40 with 5 µM CuCl2
seeds, and a seed control absent of any monomer (purple trace). D, representative gel
showing full recruitment of htau40 and htau23 monomer onto htau40 SS seeds formed
in the presence of 5 µM CuCl2. The results suggest that the Cu2+ ions are capable of
oxidizing htau40 monomer if present during nucleation of the fibrils, resulting in oxidized
fibril conformers.
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CHAPTER FIVE: SUPRESSING SELF-NULCEATION OF MONOMERS
FOR FIBRIL AMPLIFIATION ASSAY
5.1

Principles behind fibril amplification assay
Detection of minute fibril concentrations is one method for advancement of

early disease detection and therapeutic intervention of tauopathies. One way to
detect small fibril concentrations is to use an assay to amplify the initial small
fibril concentration into an easily observed fibril concentration. The Margittai lab
has previously shown observable growth in quiescent seeded reactions to be
dependent on the initial seed concentration used (119). For quiescent reactions
the lower limit of seed concentration that could be used and still result in
substantial detectable growth was 0.1% molar equivalent of the monomer in the
reaction. However, successful adaptation of an amplification assay, rather than
quiescent growth, was able to extend this limit to an approximate 4 orders of
magnitude lower seed concentration resulting in growth (119). This assay,
originally developed for prion amplification, termed protein misfolding cyclic
amplification (PMCA) assay, involves a pool of protein monomer and a minute
number of seeds undergoing cycles of sonication followed by periods of
incubation (118). The principles of the amyloid NDP growth scheme govern the
success of this assay by exploiting the fact that energetically the least hindered
type of growth is monomer addition onto fibril ends (90). By successive cycles of
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sonication (to break fibrils), followed by incubation (to allow new growth), the
number of new ends exposed is increased and overall growth is increased. A
schematic representation of this assay is shown in Figure 5.1. This assay has
been successfully used to detect fibrils from AD patient brain extract (119), but
increasing this assay’s limit of detection is desired for further applications. A
previous study from our lab, using 0.00001% molar monomer equivalent seeds,
showed amplified growth that is statistically significant from monomer controls
absent of any seed (119). That same study also identified factors critical to the
success of this assay including multiple cycles of sonication, the inclusion of
cofactor (heparin), and setting specific sonication time/power low enough that
spontaneous monomer nucleation does not occur (119). Spontaneous monomer
nucleation is not wanted because the purpose of the assay is only to amplify
fibrils from seeds. Therefore, it is vital that the monomer in the reaction be
competent to participate in elongation, but not be prone to self-nucleate. To
increase the sensitivity of this assay I explored ways to suppress the nucleation
of monomers through point mutations and modification of assay parameters.
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Figure 5.1 Schematic of cyclic amplification. Fibril seeds (blue arrows) are offered to
a pool of tau monomers (green lines). During a growth phase, monomers get
incorporated onto the fibril ends (green arrows). Elongated fibrils are then fractured by
sonication exposing new ends for additional monomers to add onto during another
growth phase. This cycle of fracture followed by incubation is repeated multiple times
resulting in a large amount of fibrils from what was initially a minute quantity of seeds.
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5.2

Suppression of monomer self-nucleation
Suppression of primary nucleation is a key factor in the success of this

cyclic amplification assay. Htau40 monomer was previously being used for this
assay, but exploring the use of mutant monomer was of interest. We
hypothesized that specific point mutations could differentially affect a monomers
nucleation and elongation capacity. Specifically, that they could suppress
nucleation without hindering the monomer’s ability to participate in elongation.
Mutations were made in the hexapeptide motif in the third repeat because this
motif has been identified to play a central role in fibril nucleation (136). The
residues of interest were β-branched hydrophobic valine at positions 306 and
309, and isoleucine at position 308. These residues were mutated into a smaller
unbranched alanine, a polar serine, or a positively charged lysine. Additional
mutations made only at position 308 include negatively charged aspartic acid and
glutamic acid. Two double mutants were also made, I308K/V309K and
I308K/V308S. Figure 5.2 highlights where the substitutions reside with respect to
the repeat region and shows the purity of all 13 mutants.
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Figure 5.2 Self-nucleation suppressing mutants. A, shows the amino acid sequence
of the four repeats of htau40 with the two hexapeptide motifs highlighted in yellow, and
the three positions where mutations were made highlighted in pink. B, SDS-PAGE with
Coomassie staining showing the purity of all 13 mutants.

Preliminary screening was done to investigate the nucleation lag phase
and the elongation competency of these mutants prior to using them in the
amplification assay. During the amplification assay, growth is not monitored in
real time, but rather assessed at the end of a given number of cycles. An
alternative approach to gain initial insight into the lag phase of mutants, with
respect to htau40, is to use ThT fluorescence monitoring growth in real time.
Mutant or htau40 monomers and heparin in a 1:2 molar ratio were quiescently
incubated at 37 °C periodically measuring the ThT fluorescence to indicate the
extent of fibril formation. The goal of these experiments was to identify mutants
that show an extended lag phase with respect to htau40, because they will most
likely also show suppressed self-nucleation in the amplification assay. The
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mutants tested showed a wide range of lag phases. Monomer with mutations to
V306 all showed a decreased lag phase with respect to htau40. Compare the
earlier time the red traces start to rise compared to the black trace in Figure 5.3
A. The decreased lag phases of these mutants make them poor candidates for
use in the amplification assay. The higher end point ThT fluorescence of V306
mutants could be attributed to them forming different structures with differential
dye incorporation, as seen previously with other mutants (21). Monomer with
mutations to only V309 were also poor candidates for use in the amplification
assay due to their very similar lag phases compared to htau40. This is evidenced
by the similar time the blue and black traces start to rise in Figure 5.3 B.
Monomer with mutations to I308, and those with double mutations to I308 and
V309, show extended lag phases compared to htau40 monomer. Notice the
delay before ThT fluorescence increase for monomer represented by green or
orange traces in Figure 5.3 C and D, compared to the black htau40 monomer
trace. Some of these I308 and I308/V309 mutants show little to no fibril
nucleation in the time frame measured (approximately 7 days). This
characteristic made these mutant monomers good candidates to do additional
screening on, and potentially use in the amplification assay.
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Figure 5.3 Characterizing lag phases of monomers with mutations in the
hexapeptide motif. ThT fluorescence was used to monitor quiescent aggregation of
htau40 and mutant monomers over several days. ThT traces for V306 mutants (A, red
traces), V309 mutants (B, blue traces), I308 mutants (C, green traces), and additional
I308 and double I308/V309 mutants (D, orange traces) all with respect to htau40 (black
trace, all panels). Traces represent the average from triplicate measurements. The scale
of the Y axis in panel A is changed due to the higher ThT fluorescence intensity of V306
mutants. These results show that, with respect to htau40, V306 mutants have shortened
lag phases, V309 mutants have similar lag phases, and I308 along with I308/V309
mutants have extended lag phases. This makes I308 mutants and I308/V309 mutants
the most promising candidates for use in our amplification assay.

5.3

Elongation competency of nucleation suppressing mutant monomers
The elongation competency of these hexapeptide mutant monomers was the

next parameter to be screened before use in the amplification assay. Despite
some having suppressed self-nucleation, if these monomers are unable to
participate in elongation reactions, they would not be useful in the amplification
assay. Using quiescent sedimentation reactions with 10% molar monomer
equivalent seed, all mutants were able to elongate onto htau40 seeds. The
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results for mutants that showed the most extended lag phase during nucleation
experiments (single I308 mutants and double I308/V309 mutants grown on
htau40 seeds) are shown in Figure 5.4. Protein being seen in the pellet following
incubation, sedimentation, and SDS-PAGE with Coomassie staining highlights
the growth of those I308 and double I308/V309 mutants on htau40 seeds (Figure
5.4 A). Growth rates for these particular mutants onto htau40 seeds were
compared using ThT fluorescence. This was done to identify if particular mutants
showed a significantly diminished growth rate. If a mutant exhibited a slow
growth rate that would exclude them from use in the amplification assay.
However, the similarity in the time to reach half max ThT fluorescence suggests
that none of these mutants had a major kinetic effect on htau40 seeded growth
(Figure 5.4 B).
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Figure 5.4 Elongation competency of mutant monomers on 10% htau40 seeds. A,
SDS-PAGE assessment of 10% htau40 seeded reactions with different mutant
monomers. P = pellet, S = supernatant. B, ThT fluorescence showing kinetics of growth
reactions between htau40 monomer (grey trace) or mutant monomers: I308A (red trace),
I308S (orange trace), I308K (yellow trace), I308D (green trace), I308E (blue trace),
I308KV309K (purple trace), and I308K/V309S (brown trace) with 10% htau40 seeds.
Error bars represent ± S.D. from triplicate measurements. These results show the
elongation competency for these mutant monomers on 10% htau40 seeds.
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5.4

Suppressed nucleation of mutant monomer during amplification
The most extended nucleation lag phase, and successful elongation of seeds

in 10% molar equivalent seeded sedimentation reactions, made the I308D,
I308E, I308K, and I308K/V309S mutants promising candidates to use in our
amplification assay. Screening experiments provided good initial data on mutant
lag phases under quiescent conditions, but how they react to the sonication
events during the amplification assay needed to be tested. In order to do this,
mutant monomers along with heparin, in a 1:4 ratio respectively, were subjected
to the assay with various parameter changes on each trial. Following the given
number of cycles for a particular trial the reactions were spun down at 128,000x
g for 30 min, pellets were separated from supernatants, and assessed on SDSPAGE with Coomassie staining as previously described. These experiments
used a wide range of systematic parameter changes in an attempt to find a
condition vigorous enough that amplification from a single fibril would be
possible, and no spontaneous monomer nucleation would occur. Parameters in
question were sonication time, incubation time, power of sonication, and total
monomer concentration. Appendix B: Amplification assay trials, provides a table
documenting some attempted combinations of parameter settings, and
qualitative notation as to whether or not particular mutants tested spontaneously
nucleated at each condition. All 13 mutants were tested, however, those
identified through quiescent nucleation to spontaneously nucleate faster than the
others were not tested as thoroughly. These experiments did show a wide range
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of variability, but highlighted two very promising experimental parameter sets that
consistently resulted in negligible nucleation of specific mutant monomers. The
first was 30 min cycles consisting of 1 min sonication at 15 percent power
followed by 29 min incubation with 10 µM tau monomer, 40 µM heparin, 1 mM
TCEP kept at a constant 37 °C. The second promising set of assay parameters
was 15 min cycles consisting of 1 min sonication at 15 percent power followed by
14 min incubation with 10 µM tau monomer, 40 µM heparin, 1 mM TCEP kept at
a constant 37 °C. The same instrument was used to collect all data shown here,
and its average power output for a 1 min sonication at 15 percent power was
7600 ± 400 J. However, operating at the same settings, a similar instrument
setup in the lab produced higher overall power output.
In the absence of any seeds, the spontaneous nucleation of the four most
promising mutants (I308D, I308E, I308K, and I308K/V309S) along with htau40
were investigated. First, using the 30 min cycle parameters for 35-65 cycles in 5
cycle increments (Figure 5.5). The results after 35 cycles show that none of the
monomer in question had gone through self-nucleation and aggregated, as
evidenced by protein being found exclusively in the supernatant after
sedimentation and SDS-PAGE analysis. After 40 cycles htau40 monomer
underwent nucleation and elongation, as protein is now found in the pellet.
However, after 40 cycles the mutants in question remain in the supernatant. This
indicates that in the context of our amplification assay, the self-nucleation of
these mutants is suppressed with respect to htau40. This trend is also present
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over 45-55 cycles, for which these mutant monomers all remain exclusively in the
supernatant. The experiment consisting of 60 cycles resulted in only one mutant
not self-nucleating to form aggregates, I308D. The remaining monomers, I308E,
I308K and I308K/V309S along with htau40, all indicate that spontaneous
nucleation and elongation occurred after 60 cycles by the presence of protein in
the pellets. The results from experiments consisting of 60 and 65 cycles show the
integrity of the monomer seems to be compromised as it appears to degrade.
This degradation is seen as smaller fragments on the lower half of the SDSPAGE gel not visible in Figure 5.5. Therefore, regardless of their lack of
nucleation, this high number of 30 min cycles appears not ideal for use with
seeded experiments.
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Figure 5.5 Nucleation suppression with 30 min cycles. SDS-PAGE with Coomassie
staining assessment of monomer aggregation following cycles of 1 min sonication 29
min incubation for 35, 40, 45, 50, 55, 60 and 65 cycles. Monomer used, from left to right
on each gel segment, htau40, I308D, I308E, I308K, and I308K/V309S. BRM = broad
range marker showing three bands with molecular weights of 97, 66 and 45 kDa, P =
pellet, S = supernatant. These results show that all mutant monomers have suppressed
self-nucleation compared to htau40, with I308D showing the most extended lag phase.
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Similar experiments were performed to examine the spontaneous
nucleation of the same five monomer types using 15 min cycles repeated 96,
144, and 192 times. These 15 min cycles consisted of 1 min sonication at 15
percent power followed by 14 min incubation with 10 µM tau monomer, 40 µM
heparin, 1 mM TCEP kept at a constant 37 °C. The results from these
experiments (Figure 5.6) show that for the 96, 144, and 192 cycles investigated,
htau40 and mutant I308E monomers have nucleated to form fibrils appearing in
the pellet upon SDS-PAGE analysis. The remaining monomers in question,
I308D, I308K, and I308K/V309S, show suppression of nucleation for experiments
consisting of 96 and 144 cycles. However, after 192 cycles nucleation has
occurred for all monomer tested. Collectively, the data from experiments using
two different cycle times reveal that mutant monomers exhibit suppressed selfnucleation with respect to htau40 monomer. The results further indicate that
suppression was the most pronounced for the I308D mutant.
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Figure 5.6 Nucleation suppression with 15 min cycles. SDS-PAGE with Coomassie
staining assessment of monomer self-nucleation following cycles of 1 min sonication 14
min incubation for 96, 144, and 192 cycles. Monomer used, from left to right on each gel
segment, htau40, I308D, I308E, I308K, and I308K/V309S. BRM = broad range marker
showing three bands with molecular weights of 97, 66 and 45 kDa, P = pellet, S =
supernatant. The results demonstrate that under the given conditions I308D mutant
monomers are most resistant to self-nucleation.

5.5

Seeded amplification using I308D mutant monomer
The monomer chosen to test the ability to amplify fibrils from low

concentrations of htau40 seeds was I308D, due to its suppressed nucleation
during multiple rounds of 30 min and 15 min cycles. Individual reactions
contained different percentages of htau40 seed, starting at 0.1% dropping in one
order of magnitude increments down to 0.000001%, and a control with no seed.
Percentages are with respect to the molar monomer equivalent in the reaction,
10 µM. The reactions were subjected to 50 cycles of 1 min sonication followed by
29 min of incubation. Pellet fractions for these experiments are shown in Figure
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5.7. Different trials are the result of biological triplicate seed batches. The same
experimental setup with decreasing seed concentration was applied to 96 cycles
of 1 min sonication followed by 14 min incubation (Figure 5.8). While the results
show variability in the amount of amplification from particular seed percentages,
they highlight the ability of the I308D mutant monomer to elongate onto low seed
concentrations. Future experiments using I308D mutant monomer are needed to
optimize assay parameters to consistently amplify fibrils from even lower
concentration of seeds. Promising preliminary data has been collected exploring
the use of an additional protein, bovine serum albumin (BSA), that does not
participate in aggregation and further suppresses tau nucleation. BSA is
potentially acting to suppress tau nucleation by preventing surface nucleation,
and reducing the collisions between tau monomers needed for nucleation. The
use of I308D mutant monomer in conjunction with BSA is anticipated to allow for
more vigorous parameters and improve detection sensitivity.
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Figure 5.7 Amplifying fibrils from dilute htau40 seed concentrations with 30 min
cycles. SDS-PAGE assessment showing pellet fractions from reactions between I308D
monomer with decreasing htau40 seed concentration using 50 cycles of 1 min sonication
followed by 29 min incubation. The seed concentrations are with respect to monomer
present in the reaction (10 µM). Trials 1, 2, and 3 are the result of biological triplicate
htau40 seed batches. BRM = broad range marker showing three bands with molecular
weights of 97, 66 and 45 kDa. The results highlight the potential for mutant monomer to
amplify fibrils from low seed concentration, and the need to further optimize assay
parameters.
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Figure 5.8 Amplifying fibrils from dilute htau40 seed concentrations with 15 min
cycles. SDS-PAGE assessment showing pellet fractions from reactions between I308D
monomer with decreasing htau40 seed concentration using 96 cycles of 1 min sonication
followed by 14 min incubation. The seed concentrations are with respect to monomer
present in the reaction (10 µM). Trials 1, 2, and 3 are the result of biological triplicate
htau40 seed batches. BRM = broad range marker showing three bands with molecular
weights of 97, 66 and 45 kDa. The results show variability in the assay, but highlight the
potential for I308D mutant monomer to amplify fibrils from low seed concentrations.
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CHAPTER SIX: DISCUSSION
6.1

Structural insights into tau fibrils reveal potential mechanism for
disparate pathology
The mechanisms underlying tau fibril propagation that result in the large

phenotypic diversity of tauopathies are not fully understood, but one explanation
is the differential propagation of fibril conformers (147). Once grown, the spread
of small fibrillar species has been shown to happen in a trans-synaptic manner.
This means the conformers that form in one particular cell can spread and induce
fibrillar growth in neighboring cells (148). This trans-synaptic propagation does
not appear to be random, but rather the sequential appearance of pathology
seems to parallel the connectivity of the neuronal network chain, as observed in
some AD patients (149). Factors that have been proposed to influence the cellto-cell transmission of certain fibrils include distinct conformational states or
PTMs (150–152). Therefore, in order to halt the pathological spreading of tau, it
is critical to have a better understanding of how distinct conformers arise, and
how their structural features influence growth properties.
It has been shown for tau and other amyloid fibrils, such as α-synuclein and
amyloid-β, that the conformation or structure of fibrils dictates their growth
properties (76, 152, 153). Also, how distinct fibril conformers composed of the
same protein type can exhibit different growth properties (97). Since the
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elongation of small fibril species proceeds in a conformationally templated
manner, and those elongated fibrils then have the potential to fragment and
recruit new monomer onto their ends (93); it is even more critical to understand
what factors contribute to how different conformers arise and recruit new
monomer. The data presented here provides mechanistic insight to growth
barriers seen with different conformers by highlighting how distinct structural
features arise due to truncations, mutations, and oxidation of the htau40 isoform.

6.1.1 Characterization of htau40 fibrils
The growth properties of htau40 fibrils were characterized by seeded
reactions monitoring end point fibrillar content using TEM or sedimentation with
SDS-PAGE assessment, and kinetics of growth via ThT fluorescence. These
experiments revealed that htau40 fibrils are able to fully recruit both htau40 (4R)
and htau23 (3R) monomers. This recruitment is not driven in any way by disulfide
bonding of native cysteines as these experiments were performed in a reducing
environment, and identical results were obtained using seeds composed of a
cysteine free version of htau40. This is a deviation from growth patterns
previously observed in our lab using seeds composed of the truncated tau variant
K18, which exhibit a 3R growth barrier (88). Variation in experimental conditions
between full-length and K18 seeded reactions did not account for their difference
in growth properties. Therefore, N- and/or C- terminal residues in htau40 appear
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to greatly influence fibril conformation and growth properties. This finding set the
stage for experiments with other truncated variants whose data is discussed in
the next section.
The structure of htau40 fibrils was probed using two types of SDSL-EPR
experiments, CW and DEER. CW experiments provided structural insight on
whether or not certain residues reside in the core of htau40 fibrils. The seven
positions investigated were in the fourth repeat and just outside it on the Cterminal end. These residues were chosen based on the cryo-EM structure of AD
fibrils, suggesting that they point to the aqueous exterior of the fibril core (19).
Spectra from all htau40 seeded fibrils suggest that all the positions investigated
reside in the structured core of the htau40 fibrils. This is in agreement with the
cryo-EM structure of AD fibrils which reveals that residues 306-378 make up the
ordered core (19).
DEER data on htau40 fibrils revealed that they are a heterogeneous
mixture of conformers. It is likely that the range of conformations stems from
tau’s intrinsically disordered nature, allowing for higher structural flexibility during
nucleation (155). This ensemble, or cloud, of conformers is shown by the multiple
peaks in the distance distributions from biological triplicate measurements of
htau40 fibrils. Interestingly, while CW EPR suggests agreement for residues
residing in the core of htau40 fibrils and published AD fibrils, the folding pattern of
the htau40 core is likely different. As evidenced by the distances in htau40 DEER
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data not matching the published AD fibril structure. However, this is not
completely surprising because AD fibrils are composed of a mixture of 3R and
4R tau isoforms, whereas the fibrils investigated here are composed of only a
single isoform. Additionally, other studies have highlighted how different
recombinant 4R fibrils are also conformationally different from published AD fibril
structure (64, 156). The different htau40 fibril structures here may be
representative of fibrils in different tauopathies, or may be novel fibril types only
existent in vitro. Selective pressures in the complex biological environment might
attribute to the differences seen between in vivo and in vitro fibrils.
It is noteworthy that the published cryo-EM structures for AD and PID
fibrils indicate different singular fold patterns for each disease (19, 20, 129), but it
is possible that there are alternative conformers with distinctly different folds
present. In clinically documented AD subtypes (128) it was shown that the
amyloid fibrils associated with AD plaques, Aβ fibrils, vary in conformation
between these subtypes (154). Additionally, it has been shown that multiple prion
conformers exist within a single brain (157).

6.1.2 Truncations can influence tau fibril structure
Many factors may contribute to the pathology of tauopathies, truncation of
tau protein is one such factor. The truncation of different proteins is a major
pathological event in neurodegenerative disorders. In addition to tau, some other
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proteins that exhibit this link between truncation and disease pathology include
TDP-43 in association with amyotrophic lateral sclerosis (158), α-synuclein in
Parkinson’s disease (159), and huntingtin protein in Huntington’s disease (160).
The truncations to tau are not random, they are the result of specific proteolytic
cleavage. Truncated variants seem to be direct participants in some disease
pathology, and the presence of truncated variants has even been suggested to
start a self-perpetuating cycle of tau truncation, increasing the rate of fibril
formation and all the effects that go with it (161).
Some of the truncated variants investigated here correspond to known
cleavage sites associated with disease truncated fragments, such as positions
421, 391 and 368 (39, 162). But as a collective group, the variants studied here
were chosen to systematically test the impact of the N- and C- terminal regions
on fibril growth. Variants with truncations to only the N- terminus, along with two
of the variants with truncations to only the C- terminus, produce fibrils that have
no 3R growth barrier. The other truncated variants that have truncations to both
the N- and C- terminus, along with 1-372 variant, produce fibrils that exhibit full
recruitment of 4R monomers. But these fibrils vary in the ability to recruit 3R
monomers, with recruitment diminishing as the variants got shorter on the Cterminal end. These results collectively indicate that C-terminal residues play a
key role in fibril conformation. The slightly diminished ability to recruit 3R tau for
the 244-421 and 244-391 with respect to the variants that contain the same C124

terminal truncation but included the entire N- terminal region, suggest some
synergistic role being played by the N- terminal residues. This potential Nterminal synergism is not unlikely, given its unstructured nature, it has the
potential to fold back and interact with other regions of the protein (163).
Structural differences between these truncated fibrils and htau40 fibrils are
likely responsible for their different recruitment properties. EPR experiments were
used to investigate the structure of truncated fibrils with a 3R growth barrier.
Comparing DEER data on htau40 fibrils and K18 fibrils (76) confirmed truncated
monomers nucleate to form fibrils structurally distinct from full-length fibrils. CW
EPR data provided more specific structural insight on K18 fibrils. Spectra from
K18 seeded fibrils revealed that residues in the beginning of the fourth repeat are
part of the structured K18 fibril core. However, the residues in the end of the
fourth repeat and just outside it are in a region of increased structural disorder,
and not part of the K18 fibril core. This is in stark contrast to the htau40 CW EPR
data that revealed a high level of order for all tested positions. This contrast in
structural order means this region that in htau40 fibrils is available for recruiting
monomers to pack against, is not available in the K18 fibrils. The reduction in
contact surface could be one explanation for the diminished 3R recruitment onto
K18 seeds, along with other structural differences in other parts of these fibrils.
The C- terminal region in fibrils extracted from 4R tauopathies, PSP and
CBD, are less structured in this region as well. Trypsin digestion of such fibrils
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revealed fragments terminating at residue 369, while the shortest fragments from
AD fibrils extended to position 385 (164). This notable similarity between regions
of structural disorder in fibrils from 4R tauopathies and the K18 fibrils investigated
here, along with their preferential recruitment of 4R tau, highlights this region of
structural disorder as a factor contributing to their preferential recruitment
(resulting in specific pathology).
A number of factors could contribute to truncated variants forming different
conformers. One example is their lack of stabilization effects that full-length tau
experiences through backfolding of residues that are not present in truncated
variants (23). The lack of these stabilizations leaves truncated tau unhindered in
its formation of other conformers during nucleation (165). The formation of
structurally distinct fibrils from truncated variants could be physiologically
relevant, as the activation of certain caspases responsible for the proteolytic
cleavage creating truncated variants has been noted to precede aggregation
(166). Also, the aggregation kinetics of truncated tau fragments are increased
with respect to full-length tau (35). This is due to the removal of the terminal
regions leaving a conformational ensemble of monomers with decreased
interference of the aggregation prone regions. This results in a lower energetic
barriers for self-association, meaning that if present, these truncated species
have an advantage to initiate fibril formation over full-length tau (30). Due to
growth via conformational templating on the initial seed, if a truncated variant that
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has a growth barrier initiates fibril formation, that conformer could preferentially
recruit full-length 4R tau and be propagated. This could ultimately result in
preferential deposition of fibrils that were initiated from a truncated variant seed,
but after elongation are mostly composed of full-length tau. Truncated variants
are not associated with all tauopathies, but understanding how truncations can
influence conformation and growth properties is useful to understand overarching
propagation principles. Truncated variants that show no preferential growth, but
are still structurally distinct, could be responsible for particular pathology in other
disease states.

6.1.3 Mutations impact tau fibril structure
Some of the numerous mutations associated with tau protein show
correlation to preferential isoform deposition in certain diseases. One potential
explanation for the preferential deposition of some of these mutant fibrils is their
effect on the splicing of exon 10, changing the ratio of 4R/3R tau available to
participate in aggregation (24). However, since not all mutants take effect at the
RNA level, other mechanisms must be responsible for their preferential
deposition. To probe the potential influence certain mutations have on forming
conformationally distinct fibrils with differential recruitment properties, specific
mutants were investigated. I explored growth properties of fibrils with mutations
to the proline at position 301 in full-length 4R tau, along with growth properties of
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mutants flanking position 301. Mutations to the proline at position 301 are of
particular interest because of their association with familial 4R tauopathies (167,
168), and lack of splicing alteration (135). Insight on P301S and P301L mutant
fibrils is also of particular interest because multiple research models utilize these
particular mutations (169).
The fibrils formed from P301 mutant monomer show recruitment of 4R
monomer (>80% growth), but a robust growth barrier towards 3R monomer
(<15% growth). This barrier was confirmed using sedimentation assays, ThT
fluorescence, and visualized using TEM. Htau40 monomer is able to grow on
P301 mutant seeds, but this growth is significantly slower than homotypic
recruitment for either mutant type of seed, as shown by ThT kinetics. This
suggests that while non-mutant htau40 can assume the preferred mutant
conformation, this conformation is energetically less favorable to non-mutant
htau40. EPR data revealed structural contrast between these P301 mutant fibrils
and the htau40 fibrils. Specifically, that P301 mutants possess structural disorder
in the second half of the fourth repeat and the residues immediately outside it,
and are an ensemble of conformers distinct from htau40 fibrils. The structural
difference of these mutant conformers is significant enough that it does not
provide the contact surface necessary for 3R growth, resulting in only minimal
overall recruitment. The preferential recruitment of 4R monomer displayed by
these P301 mutant fibrils aligns with their pathology in vivo, as they are known to
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be associated with 4R tauopathies (24). Since they have been shown to not shift
4R/3R expression ratios (135), one mechanism of their preferential recruitment in
vivo could be due to the mutation promoting specific conformer formation during
nucleation.
The significant 3R growth barrier observed with P301 mutant fibrils is very
specific to mutating the proline at position 301. This effect is not due to the
proximity of position 301 to the PHF6 motif, a region vital for initiating
aggregation (136). This is evidenced by the failure of six other mutations flanking
position 301 to form fibrils with a strong 3R growth barrier. These included both
known disease mutants associated with 4R tauopathies (24), and synthetic point
mutations in the PHF6 motif. The lack of conformational distinction as the
mechanism behind the preferential deposition of the other disease mutants is
unsurprising given that these particular mutations have been identified to take
effect at the RNA level shifting the splicing expression 4R tau over 3R tau (170–
172). Therefore, a conformational difference would be an additional mechanism
for their preferential recruitment properties. The synthetic point mutations had the
potential to disrupt β-sheet packing by the insertion of a charged residue into the
PHF6 motif. However, they also exhibited no growth barriers. The findings
highlight the vital role the proline at position 301 plays in determining fibril
conformation.
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Insight as to how this single proline mutation is capable of changing the
overall preferred conformation of the fibril was gained from other published
structures. The fibril cores from AD and PID patients have been shown to contain
distinctly different folds (20). Core region sequence comparison reveals the
pattern of β-strands align fairly well between these fibrils, and their two distinct
fold patterns mostly arise from how the residues linking these strands together
are oriented (20). There are either two or three PGGG motifs found in the core
regions of these AD and PID core structures, and all are found in these linker
regions. Falcon et al. used core structures to highlight the flexible nature of the
PGGG motif and its ability to take on multiple conformations, such as turns,
spirals, or extended arrangements (20). The data presented in the current study
is in agreement with their suggestion that this motif can be a key determinant for
overall core structure. A model of PID and AD fibril core structures utilizing PDB
data bank accession numbers 6GX5 and 5O3L respectively are depicted in
Figure 6.1, with red segments highlighting the PGGG motifs and their flexible
nature. Notably, the proline mutated in the current study is part of one of the four
PGGG motifs in htau40. The particular motif that contains 301 lies just outside
the core region for published AD structure, but unresolved density in these cryoEM maps suggests that this motif assumes a turn structure and will back fold to
pack against β-strands in the third repeat region (19). It is possible that the
growth barrier shown here with P301 mutant fibrils is the result of a different
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orientation of this motif, such as an extension, as suggested in a previous study
(173).

Figure 6.1 Model of PID and AD fibril core structures. Utilizing PDB accession
numbers 6GX5 and 5O3L for PID and AD fibrils respectively, the PGGG motifs for each
have been identified in red. These segments display a high level of flexibility and their
presence in the linker regions between β-strands allows for alteration to fold pattern of
the core. Given their influence on structure, mutations to these residues have the
potential to shift preferred conformers resulting in differential growth properties.

Notice, the G303V mutation did not have a large structural effect despite
its inclusion in one of these PGGG motifs. This switch exhibits a less drastic side
chain alteration than a mutation to the proline at position 301 exhibits. The
unique cyclic side chain structure and ability of proline to assume the cis or trans
configuration allows for its greater influence on structure (174). It is also
interesting to note that one of these PGGG motifs is found towards the end of
each microtubule binding repeat. The proline in each is found at position 270,
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301, 332, or 364; all of which have been identified as pathogenic mutation points.
The P270 mutant fibrils are not associated with a clinical phenotype, yet they do
correlate to FTD pathology (175). The P332 and P364 mutants have been
associated with FTD and present with Pick body-like inclusions (176). Studies
probing the growth and structural properties of these mutants would be of interest
to identify if they influence 4R or 3R tau recruitment. Collectively, the mutant data
presented here highlight how mutations to key structural motifs can significantly
alter fibril conformation implicating a mechanism for their preferential growth
properties in disease.

6.1.4 Oxidation of htau40 results in structurally distinct fibrils
Recruitment properties of htau40 fibrils composed of monomers that
possess an intramolecular disulfide bond between their two native cysteines
were of particular interest for a continued investigation of structural diversity in
tau fibrils. Due to tau’s intrinsically disordered nature, it’s set of
thermodynamically accessible states as a monomer is greatly increased in
comparison to other natively folded proteins. This makes characterization of its
monomeric state before it transitions to be part of a fibril difficult (55). However,
identification of conformational states that are thermodynamically favored and
have the potential to participate in fibril growth can be identified, this is helpful in
understating particular growth properties (142). The interest surrounding
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intramolecularly disulfide bonded htau40 was due to its potential restriction of
monomer conformational states from the disulfide bond holding it in a different
conformation than it would natively assume without this bond. The data
presented here suggests this different preferred conformer promotes the
formation of fibrils with distinct structure and growth properties from their reduced
counterparts. These distinct conformers could potentially correspond to disparate
pathology associated with certain diseases.
Htau40 monomers containing an intramolecular disulfide bond (htau40
oxidized) were isolated and used to form initial seed fibrils. The growth properties
of these fibrils were investigated using sedimentation, ThT kinetics, and TEM.
Growth in homotypic oxidized seeded reactions suggests these oxidized seeds
do recruit oxidized monomers. However, these oxidized seeds exhibited a lack of
recruitment of htau40 SS, htau40 AA, htau23, and htau40 crosslinked
monomers. It is unlikely there is even any minor conformer present in the
oxidized seed population that could recruit cysless variants, as a complete
growth barrier was observed when htau40 SS monomers were offered to 50%
(molar monomer equivalent) htau40 oxidized seeds. The lack of growth when
offering an htau40 variant with its two native cysteines crosslinked with a
bismaleimide crosslinker possessing an 8 Å spacer arm suggest the importance
of specifically a disulfide bond linking the cysteines. The rationale behind using
the crosslinked version of htau40 was to mimic the compact structure of the
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htau40 oxidized monomer. This allowed us to test whether or not alleviating the
energetic barrier to bring the monomer into a relatively compact structure would
be enough to then allow for monomer addition. However, while this crosslinker
does restrict the monomer conformation, it is not as compact as monomer
possessing just a disulfide bond. The 8 Å spacer between maleimide groups in
this linker is likely too large, and rather than mimicking the tight compact
structure of oxidized monomer this crosslinked variant is rather distended in
comparison. The inability of crosslinked monomer to be recruited to oxidized
seeds suggests tight spatial constraint created by the disulfide bond, and
perhaps it’s thiol properties, are significant factors determining the recruitment of
monomer to oxidized fibrils.
Additional experiments investigated the necessity of the disulfide bond in
monomer elongating on htau40 oxidized fibrils. These results suggested that if
the monomer has the chance to oxidize over time, it will then be able to add onto
the oxidized seeds. Collectively these results from various heterotypic growth
reactions reveal that the recruitment of monomer onto htau40 oxidized seeds is
dependent on the capacity of the monomer to form an intramolecular disulfide
bond. This in complete contrast to reactions utilizing htau40 reduced fibrils that
do not possess intramolecular or intermolecular disulfide bonds. These htau40
reduced fibrils are formed in the presence of reducing agent, and their growth
properties are independent from any disulfide bond influence. This is evidenced
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by their full 4R and 3R tau recruitment properties showing no correlation to
cysteine content. Also, these fibrils contained no higher order species, as
confirmed through SDS-PAGE assessment of htau40 reduced fibrils with sample
buffer lacking reducing agent showing no dimer, trimer, or higher order species
(data not shown). Collectively these differential recruitment properties suggest
htau40 oxidized fibrils are structurally distinct from htau40 reduced fibrils.
Due to the inability of these oxidized fibrils to recruit cysless monomer,
EPR techniques to probe the structure of htau40 oxidized fibrils are not available.
However, additional experiments were performed to highlight the structural
differences between these oxidized and reduced fibrils. These included the
comparison of denaturation profiles, digestion products, and conformational
stabilities for these two fibril types. Denaturation by GdnHCl revealed that
oxidized fibrils are more susceptible to denaturation than reduced fibrils,
suggesting different regions of the protein are exposed implying they are
conformationally distinct. Limited protease digestion resulted in different digestion
products, suggesting the core structure of these fibrils are different to expose
different cleavage sites. Finally, different fibril lengths were observed after
applying the same sonication stress to oxidized and reduced fibrils, with reduced
fibrils displaying on average a longer length than oxidized fibrils. Since a fibril’s
stability can be influenced by its structural features, these fragility differences
suggest these fibrils are structurally distinct.
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These differences, along with the different recruitment properties,
collectively reveal that oxidized and reduced fibrils are structurally distinct from
one another. The understanding that an intramolecular disulfide bond within 4R
tau can impact fibril structure resulting in unique recruitment properties highlights
another mechanism of how growth barriers can arise in certain disease states.
Further investigation would need to be done to determine whether or not the
distinct structural aspects of these oxidized fibrils correlate to fibrils from
particular disease states with increased oxidative stress associated with them. A
previous in vitro study, using different variations of 4R oxidized and reduced
fibrils from those discussed here, also highlighted different properties between
the two fibril types (57). Interestingly, following trypsin treatment they identified
peptide differences. This insight, along with the data from this current study,
suggests how disulfide bonds influence regions of structural order and can
impact growth properties.
In addition to being structurally distinct from reduced fibrils, these oxidized
fibrils also exhibit a unique characteristic of being able to be partially dissociated
upon treatment with reducing agent. The observation that there is a maximum
extent to this dissociation suggests these oxidized fibrils, like all other fibrils
investigated via DEER analysis discussed previously, are an ensemble of
conformers. It is likely that the entire population of fibrils with a similar
conformation are being dissociated, while different fibril conformers remain. This
136

is suggested by the presence of monomeric species following treatment with
reducing agent, and the assumption that fibrils do not change conformation along
the long axis of the same fibril. If one monomer can be removed from the end,
the whole fibril will most likely be dissociated. These fibrils that can be
dissociated may not be structurally identical, yet it is likely they share common
features. These include the disulfide bond being accessible to reducing agent
and being the dominant structural feature of these fibrils, therefore breaking this
bond results in their dissociation. The population of conformers that cannot be
dissociated is likely different in that the disulfide bond is either not the only
structurally significant feature (therefore breaking it does not result in
dissociation), or the fibril conformation is such that the bond is not accessible to
any reducing agent. This feature makes these non-dissociated fibrils of particular
physiological interest. It has been previously suggested that intramolecularly
disulfide bonded tau may be acted upon differently by proteolytic and degradative
machineries acting to clear pathological tau from cells (34, 56). Additionally,
under particular oxidative stress conditions, the typical glutathione concentration
in the cytosol can be reduced (177, 178). This would allow for oxidation of tau,
and previous studies have shown that under oxidizing conditions 4R tau
preferably forms intra over intermolecular disulfide bonds (179). It is noteworthy
that dimers created by intermolecular disulfide bonded tau have displayed a
similar binding affinity for MT as monomeric non-oxidized tau (180). Yet, it is
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unclear whether or not this is also true for intramolecularly disulfide bonded tau. If
an intramolecular disulfide bond does decrease 4R tau’s native function,
oxidation is an important factor diverting them toward fibril formation.

6.2

Optimization of tau amplification assay
The increase in prevalence of tauopathies has made early detection

techniques and therapeutic design the subject of numerous studies. There are
currently multiple approaches to improving early detection. Radiotracers in
conjunction with PET imaging (115) and detection in blood or cerebrospinal fluid
samples (148, 181, 182) are some techniques currently being pursued. Tau
imaging via PET tracers have recently been reported to show promising results
for human testing, with potential to monitor disease progression and treatment
response (116). Alternatively, the cell-to-cell transfer of small aggregates make it
possible that even in early disease stages tau could be present in extracellular
fluid (148, 183). However, the amount of tau fibrils would be extremely small, and
an extremely sensitive assay would be needed in order to detect it (184).
Immunodetection and amplification assays are two potential methods for this
detection. Immunoprecipitation of full-length and truncated tau fragments is a
powerful detection tool, yet the epitope specificity of the antibodies used can
potentially result in some tau species not being detected (185), or fail to
distinguish between normal and pathological tau (113). Amplification techniques
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could be used as a precursor or in conjunction with immunodetection techniques,
or the PET imaging strategy, to develop the best approach to early detection.
The previously developed PMCA assay for prion amplification (118) has
been successfully modified in our lab to amplify small concentrations of tau fibrils
(119). However, improving the sensitivity of this assay was desired. One way to
improve assay sensitivity is to suppress monomer self-nucleation. Previous
studies have shown a hexapeptide motif at the beginning of the third repeat to
have high inclination to form the β-structure, and that point mutations in this
region decreased aggregation propensity (136). That knowledge led us to
investigate the effect that specific point mutations within the hexapeptide motif
(PHF6) have on spontaneous nucleation. The data presented here show an
extended lag phase, and elongation competency with high seed concentrations
for monomer with mutations to I308, and monomer with double mutations to I308
and V309. The I308 mutants, and one double I308/V309S mutant were used in
our amplification assay. Again, these mutant monomers showed suppressed selfnucleation for multiple parameters tested. Reactions with I308D monomer and
decreasing concentrations of recombinant htau40 seeds were also subjected to
the amplification assay protocol. The seeded reactions utilizing I308D monomer
do show amplification from low seed concentration. However, to enhance the
robustness and sensitivity of this assay, additional experiments need to be
performed. The data presented here is significant as it highlights how specific
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mutations can differentially affect nucleation and elongation competency. Also,
the suppressed nucleation of mutant monomer importantly suggests the
sensitivity of this assay has the potential to be enhanced.
Multiple factors can contribute to the variability seen with the amplification
assay. Previous studies and this current study suggest that fibril nucleation, for
multiple monomer types, results in a population of conformers (21, 64, 76).
These conformers could have different responses to selective pressures, some
with a higher probability of nucleation, resulting in the inconsistent amount of
monomer self-nucleation. The ensemble-like nature of free monomer cannot be
avoided; however, other points of variability in seeded reactions could be
addressed. This would involve teasing apart the experimental parameters to
identify how systematic changes to each parameter affect experimental results.
For instance, to account for growth rate and fragility of fibrils, the time of
incubation and sonication, along with the power of sonication must be
considered. The trends exhibited by each parameter change need to be
characterized such that different settings can be chosen and confidently applied
universally to samples, or ideal settings applied to particular samples.
Along with characterization of how individual parameters effect
amplification, future work could involve double mutations in the PHF motifs
between residues 306-311 and 275-270. Mutations to both these regions could
potentially diminish spontaneous nucleation even more as these two motifs have
140

been suggested to cross-talk during aggregation (173). Also, given the sensitivity
of this assay, experimental technique during reaction preparation needs to be
considered. Experimental technique that minimizes the agitation during mixing
and transfer, yet still prepares homogenous reactions is desired. A protocol that
optimizes this preparation could alleviate variability. A parameter that can also
contribute to variability of this assay is intrinsic power variation from the sonicator
horn. This has also been noted by other groups utilizing sonicator horns for
PMCA experiments as well (186).
Although optimization is still needed, the studies here provide a significant
step toward enhancing the sensitivity of this amplification by identifying mutants
with suppressed self-nucleation. Once optimized, this assay could be used in
conjunction with immunodetection techniques, or inform the optimization of other
detection assays. Given the potential to detect tau fibrils in blood samples, once
optimized, this assay could act as a routine precursor check before any more
invasive detection or treatment techniques are pursued.
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APPENDIX A: TAU PURIFICATION

Representative trace from cation exchange chromatography.
Chromatograph for a sample of htau40 showing utilizing a Mono S 10/100 GL
cation exchange column monitoring absorbance at 280 nm (blue trace). Linear
gradient of 1000 mM NaCL starting at 0% and ending the run at approximately
35%, mixing with a 50mM NaCl buffer (light green trace). Conductivity trace
(brown trace) showing increase parallel to linear gradient of high salt buffer
causing tau to elute off the column between approximately 25-30 mS/cm. Elution
volume was collected in 3 mL fractions and assessed via SDS-PAGE before
proceeding to gel filtration.
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Representative trace from gel filtration chromatography. Chromatograph for
an htatu40 sample run over a column with Superdex 200 media. Absorbance
measured at 280 nm (blue trace). Elution volume collected in 5 mL fractions.
Based on its size the peak starting around fraction 49 is htau40, fractions
containing this peak were run on SDS-PAGE to be assessed before precipitation.

Representative purification gels from ion exchange chromatography and
gel filtration chromatography. A, SDS-PAGE assessment of fractions 11-17
from an ion exchange sample of htau40, fractions 14-17 were pooled and
subjected to gel filtration. B, SDS-PAGE assessment of fractions from a gel
filtration sample of htau40, fractions 51-55 were pooled and let precipitate
overnight in a 1:1 ratio with methanol along with 2 mM DTT.
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APPENDIX B: AMPLIFICATION ASSAY TRIALS

Table 1. Combinations of amplification assay parameters tested. Top
horizontal row indicates the parameter in question. Left most column indicates an
arbitrarily assigned ID to each combination of parameters, ID’s are used in table
2 for results of particular monomers for different parameter combinations.

Table 2. Qualitative results for different amplification assay parameters
with different mutants. Top horizontal row indicates the type monomer used.
The left most column identifies the ID for the specific assay parameters detailed
in Table 1. For each particular monomer/parameter combination Y indicates
spontaneous nucleation occurred and N indicates spontaneous nucleation did
not occur. Y or N determinations were made based on SDS-PAGE assessment
of pellet and supernatant fractions following experiments.
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APPENDIX C: TAU VARIANTS
Sequence of htau40
10
20
30
40
50
60
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQTPTEDGSEEPG
70
80
90
100
110
120
SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG
130
140
150
160
170
180
HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK
190
200
210
220
230
240
TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK
250
260
270
280
290
300
SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV
310
320
330
340
350
360
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI
370
380
390
400
410
420
THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV
430
440
DSPQLATLAD EVSASLAKQG L

Sequence of htau23
10
20
30
40
50
60
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKAEEAGI GDTPSLEDEA
70
80
90
100
110
120
AGHVTQARMV SKSKDGTGSD DKKAKGADGK TKIATPRGAA PPGQKGQANA TRIPAKTPPA
130
140
150
160
170
180
PKTPPSSGEP PKSGDRSGYS SPGSPGTPGS RSRTPSLPTP PTREPKKVAV VRTPPKSPSS
190
200
210
220
230
240
AKSRLQTAPV PMPDLKNVKS KIGSTENLKH QPGGGKVQIV YKPVDLSKVT SKCGSLGNIH
250
260
270
280
290
300
HKPGGGQVEV KSEKLDFKDR VQSKIGSLDN ITHVPGGGNK KIETHKLTFR ENAKAKTDHG
310
320
330
340
350
AEIVYKSPVV SGDTSPRHLS NVSSTGSIDM VDSPQLATLA DEVSASLAKQ GL
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Variant

Average molecular weight (kDa)

1-441, htau40

45850

1-352, htau23

36760

151-441

30649

244-441

21119

1-421

43869

1-391

40738

1-372

38602

244-421

18950

244-391

15819

244-384

15080

244-378

14411

244-372, K18

13682

244-368

13184
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APPENDIX D: RECIPES
Extraction Buffer:
500 mM NaCl
20 mM PIPES
5 mM EDTA

Cation Exchange Buffer: A
50 mM NaCl
20 mM PIPES
0.5 mM EDTA
* 0.45 µm filtered

Cation Exchange Buffer: B
1000 mM NaCl
20 mM PIPES
0.5 mM EDTA
* 0.45 µm filtered

Size Exclusion Buffer:
100 mM NaCl
20 mM TRIS
1 mM EDTA
* 0.45 µm filtered

Assembly Buffer: pH 7.4
100 mM NaCl
10 mM HEPES
0.1 mM NaN3
* 0.45 µm filtered

10 X SDS Running Buffer:
190 mM Glycine
25 mM TRIS
0.1 % SDS

NZY Broth: (autoclaved)
10 g/L N-Z Amine
5 g/L yeast extract
5 g/L NaCl
*immediately before use
add: 12.5 mM MgCl2
12.5 mM MgSO4
10 mM glucose

Kanamycin Culture Plates:
20 g/L LB broth
10 g/L LB agar
*once autoclaved cool to 55
°C add 50 mg/L kanamycin

Coomassie Stain: (0.5 L)
200 mL Methanol
50 mL Acetic Acid
250 mL DI water
1 g Coomassie
*mix well then filter

Destain: (2 L)
100 mL Methanol
250 mL Acetic Acid
1650 mL DI water

Separating Gel Buffer:
1.5 M TRIS
14 mM SDS
*pH to 8.8 with HCl

Stacking Gel Buffer:
0.5 M TRIS
14 mM SDS
*pH to 6.8 with HCl

Stacking Gel:
61% water
13% Bisacrylamide
25% stacking gel buffer
1% SDS (10% solution)
*right before use add:
0.6% APS (10% solution)
0.06% Temed

Separating Gel: (12%)
35% water
38% Bisacrylamide
25% separating gel buffer
1% SDS (10% solution)
*right before use add:
0.6% APS (10% solution)
0.06% Temed

Separating Gel: (15%)
23% water
50% Bisacrylamide
25% separating gel buffer
1% SDS (10% solution)
*right before use add:
0.6% APS (10% solution)
0.06% Temed

SDS Sample Buffer:
62.6 mM TRIS
*pH to 6.8 with HCl
4% SDS
10% sucrose
5% βME
*completely mix then add 6
mM Bromophenol Blue
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APPENDIX E: MATERIALS AND INSTRURMENTS
Material/
instrument
DNA primers

Manufacturer
Integrated DNA
Technologies

Product/
CAT #

general usage
making point
mutations
site-directed
mutagenesis kits
primer and DNA
dilutions, PCR
reactions

important
specifications
melting point <65 °C
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QuikChange II

Agilent Technologies

200524-5

polymerase: PFU ultra

PCR certified water

Teknova

W3340

MJ Mini Personal Thermal
Cycler

BIO RAD

PTC-1148

PCR cycles

QuikChange XL1- Blue
supercompetent cells

Agilent Technologies

200518-41

transforming PCR
product

optimized for DNA
amplification

BL21 (DE3) cells

Agilent Technologies

200131

transforming pure
DNA

Polypropylene round-bottom
tubes

Falcon

352059

transformation

optimized for
expression
shape and polymer
optimized for heat
shock step

N-Z amine

Sigma

N4517

NZY mixture for
transformation

Yeast

Difco

0127-17-9

NZY mixture for
transformation

Magnesium Sulfate
heptahydrate

Fluka

63138

NZY mixture for
transformation

Magnesium Chloride

Sigma

M-8266

NZY mixture for
transformation

Glucose

Sigma

G8270

NZY mixture for
transformation

ACS reagent grade

Kanamycin

Gold Biotechnology

K-120-25

antibiotic included in
all bacterial growth

Luria-Bertani broth (Miller)

Difco BC

214-906

bacterial growth
media

LB Agar Miller

Fisher Bioreagents

BP-1425-500

culture plates

Fisher Scientific

FB0875713

bacterial growth
media for culture
plates
hold solidified LB
agar on which
bacterial colonies
grow
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Plasmid MIDI kit

Qiagen

12145

DNA purification

Isopropanol

Fisher Scientific

A415-4

DNA precipitation

UV/Vis spectrometer

Varian

Cary 100Bio

any measurements in
the UV/Vis
wavelength range

MaxQ4000 Incubator

Thermo Scientific

SHKE4000-7

shaking at 200 rpm
for bacterial growth

Incubator

Barnstead Lab-Line

150

bacterial growth on
culture plates

Isotemp Incubator

Fisher Scientific

all seeded reactions,
seed fibril formation
and any 37 °C
incubation that was
not a culture plate

pET28b plasmid used
is Kanamycin resistant
powder, Miller's
modification 10 g/L
NaCl

100 mm x 15 mm
sterile polystyrene
appropriate volume
scale for extracting
DNA from a 50 mL
starter culture
molecular biology
grade

always set to 37 °C,
can hold the weight of
6 L of expression+
glass flasks
always set to 37 °C,
only used for culture
plates no tau reactions
always set to 37 °C,
internal plug so stir
plate can be inside
incubator for seed fibril
formation

Refrigerated circulation bath

Neslab

water bath

Precision

Sorvall LYNX 6000
centrifuge

Thermo Scientific

RTE4

heat shock for
transformation
heat expression
homogenate at 80 °C
for 20 min

75006590
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Isopropyl β-D-1thiogalactopyranoside
(IPTG)

Gold Biotechnology

12481C100

Sodium Chloride

J.T. Baker

4058-06

piperazine-N,N’-bis(2ethanesulfonic acid) (PIPES)

Research Products
International

5625-37-6

ethylenediaminetetraacetic
acid (EDTA)

Fisher Scientific

S311-3

β-mercaptoethanol (βME)

Fisher Bioreagents

BP176-100

Sonifier

Fisher Scientific

Model 40:0.15:4C

ammonium sulfate

MP Biomedicals

808237

any centrifugation in
50 mL tubes or 1 L
Nalgene bottles
induce protein
expression since tau
gene is under the
control of the lac
operator
used in making
buffering solutions
used in making
buffering solutions
used in making
buffering solutions
added to expression
homogenate and
ingredient in sample
buffer
sonication steps
during purification
protocol
salting out tau protein

sensitive enough to
accurately hold at 42.5
°C for transformation
heat shock
capable of getting to 80
°C and holding >12 50
mL conical tubes
interchangeable rotors,
temperature control,
robust because it gets
a lot of usage
0.5 mM working
concentration

ultrapure
high purity, pH 6.5

equipped with a
Branson 6-mm tip
gentle salting out
results in better yields

dithiothreitol (DTT)

Gold Biotechnology

DTT100

syringe filter

Acrodisc

PN-AP4558

Akta FPLC

GE Healthcare

Cation exchange column

GE Healthcare

150 mL superloop complete

reducing agent during
purification
sample filtration prior
to ion exchange
chromatography

protease free, must be
prepared fresh daily
GxF/GHP, pore size
0.45 µm
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purification

robust, dual pump
system

17-5169-01

purification

mono S 10/100 GL

GE Healthcare

18-1023-85

purification

pressure limit 2 Mpa

Protogel

National Diagnostics

EC-890

making 12% and
15% gels

30% (w/v) Acrylamide:
0.8% (w/v) BisAcrylamide

trizma base (TRIS)

Sigma

T1503

ingredient in gels and
size exclusion buffer

crystalline

sodium dodecyl sulfate
(SDS)

J.T. Baker

4095-02

ingredient in gels and
gel running buffer

ultrapure

ammonium persulfate (APS)

Fisher Scientific

A682-500

ingredient in making
gels

temed

BIO RAD

161-0801

ingredient in making
gels

glycine

Fisher Bioreagents

BP381-5

ingredient in gel
running buffer

white crystals or
crystalline powder

sucrose

MP Biomedicals

821713

ingredient in sample
buffer

ultrapure

bromophenol blue

Sigma-Aldrich

114391

ingredient in sample
buffer

powder form

Coomassie Brilliant Blue

Thermo Scientific

20278

ingredient in stain
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Methanol

Fisher Chemical

A456-4

ingredient in stain,
destain, and used for
protein precipitation

Acetone

Fisher Chemical

A929-4

protein precipitation

acetic acid

Fisher Chemical

A490-212

ingredient in stain
and destain

Akta Purifier

GE Healthcare

10 mL superloop complete

GE Healthcare

56301597

purification

XK 26/100 chromatography
column

GE Healthcare

28988951

size exclusion
chromatography

Superdex 200

GE Healthcare

17-1043-01

size exclusion
chromatography

Superdex 75

GE Healthcare

17-1044-01

guanidine hydrochloride
(GdnHCl)

Thermo Scientific

24115

guanidine hydrochloride
(GdnHCl)

Fisher Biochemicals

BP178-1

PD10 desalting columns

GE Healthcare

17-0851-01

monomerization

4-(2-hydroxyethyl)-1piperazineethanesulfonic
acid (HEPES)

J.T. Baker

41153-05

Assembly buffer

gel filtration
chromatography

size exclusion
chromatography
dissolving protein
pellets for
monomerization and
guan melt
experiments
cleaning PD10
columns and stir bars

precipitate proteins
larger than 200 amino
acids
precipitate proteins
smaller than 200 amino
acids

dual pump system,
very robust

large size so 10 mL
samples can be sent
over it
for proteins >200
amino acids
for proteins <200
amino acids

liquid, 8 M, ultra pure

crystals, make 6-8 M
stock
clean before and after
each use, ~20 uses per
column
pH 7.4
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sodium azide

Fisher Scientific

26628-228

Assembly buffer

granular

Nylon Membrane Filter

Whatman (GE
Healthcare)

7404-004

vacuum filtration filter

0.45 µm

bicinchoninic acid protein
Assay kit

Pierce, Thermo
Fisher Scientific

23225

protein concentration
determination

make a standard curve
each time do not use
extinction coefficient

tris(2carboxyethyl)phosphine
(TCEP)

Gold Biotechnology

TCEP25

reducing agent once
protein is pure

high purity

Heparin

Celsus

EN-02912

necessary for all tau
aggregation
experiments

low molecular weight
~4400 kDa

Teflon-coated micro stir bar

Big Science Inc

SBM-0502-MIC

initial fibril formation

PTFE 5 x 2 mm micro

Microcentrifuge tubes

MultiMax

3466

initial fibril formation

2 mL, flat bottom so stir
bar can freely rotate

microcentrifuge tubes

Beckman Coulter

357448

any
ultracentrifugation

polypropylene, 1.5 mL

L7-55 ultracentrifuge

Beckman

ultracentrifuge rotor

Fiberlite

F45L-24x1.5

any
ultracentrifugation

Sonifier

Fisher Scientific

Model 100

breaking initial fibrils
to create seeds

Thioflavin T (ThT)

Sigma

T3516

monitoring reaction
kinetics

syringe filtered

FLUOstar Omega plate
reader

BGM Labtech

monitoring reaction
kinetics

excitation/emission
filters 440/480 nm

any
ultracentrifugation
ran at 128,000 x g, but
max is ~211,000 x g
equipped with a 2-mm
tip, at power setting 2
output of 4 ± 1 w(RMS)
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Optical Btm Plt
Polymer/Base plate

Nunc, Thermo
Scientific

265301

monitoring reaction
kinetics

96 wells, N/Treated
N/SterPS

100-1250 µL pipet tips

VWR

89079-470

pipetting

autoclaved before use

1-200 µL pipet tips

VWR

89079-446

pipetting

autoclaved before use

0.1-10 µL pipet tips

VWR

89079-464

pipetting

autoclaved before use

specialty gel loading tips

Fisherbrand

02-707-181

loading gels and
supernatant removal

autoclaved before use

Formvar/ Carbon 200 mesh
copper grids

Electron Microscopy
Sciences

FCF-200-Cu

visualizing
aggregates via TEM

uranyl acetate

Electron Microscopy
Sciences

22400

staining aggregates
for TEM

T12 Biotwin Electron
transmission microscope

FEI Tecnai

[1-oxyl-2,2,5,5-tetramethylΔ3-pyrroline-3methyl]methanethiosulfonate
(MTSL)

Toronto Research
Chemicals

[1-acetyl-2,2,5,5-tetramethylΔ3-pyrroline-3methyl]methanethiosulfonate

Toronto Research
Chemicals

spin dilution for EPR
samples

EMX Plus spectrometer

Bruker

CW EPR
measurements

ER 4119HS resonator

Bruker

CW EPR
measurements

electron microscopy

875000

EPR spectroscopy

2%, 0.2 µm syringe
filtered
owned by University of
Colorado, Boulder,
using high tension of
100 KV and a Gatan
CCD camera
powder taken up in
DMSO to 40 mg/mL for
usage
non-paramagnetic
analog of MTSL, also
taken up in DMSO to
40 mg/mL
operating at X-band,
room temp

capillary tubes

Vitrotubes

quartz Q-band tubes
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CW EPR samples

0.6 ID x 0.84 OD

VITROCOM

DEER samples

SFS round cell 1.1 mm
ID

ELEXSYS E580
spectrometer

Bruker

DEER measurements

ER 5107D2 dielectric
resonator

Bruker

DEER measurements

580-400U ELDOR unit

Bruker

E5803006

DEER measurements

second microwave
source

10 W amplifier

Bruker

HA8019

DEER measurements

increase sensitivity

Oxford CF935 cryostat

Mercury iTC

ITC503

DEER measurements

maintain 80 K using
liquid nitrogen

hydrogen peroxide

Sigma-Aldrich

216763

Oxidation of htau40

30% (w/w) in H2O

Dialysis tubing

Spectra/Por

132676

dialysis

centrifugal filter units

Amicon Ultra

UFC501024

spin concentration

Superdex 200 10/300 GL

GE Healthcare

anaerobic chamber and
glove box

Coy Lab Products

Coy Anaerobic Monitor
(CAM-12 detector)

Coy Lab Products

CV6084

28990944

size exclusion
chromatography for
oxidation
experiments
anaerobic
experiments
anaerobic
experiments

flat width 10 mm,
molecular weight cutoff
12-14 kDa
molecular weight cutoff
10 kDa
bed volume ~24 mL

Oxygen content was
kept between 10-20
parts per million

proteinase K (PK)

Promega

V30213

limited protease
digestion

phenylmethylsulfonyl
fluoride (PMSF)

Sigma

P-7626

stop proteolysis

Mini-PROTEAN TGX stainfree gels

Bio-Rad

456-8095

visualize protease
digestion products

4-20% precast gradient
gel

bis(maleimido)ethane
(BMOE)

Thermo Scientific

22323

crosslinking cysteines
in htau40

power, taken up in
DMSO to 20 mM

nontreated black bottom 96
microwell plates

Thermo Scientific

237105

amplification assay

clear polyolefin sealing tape

Thermo Scientific

232702

sealing plates for
amplification assay
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ultrasonic processor

Qsonica

Q700

amplification assay

temperature control unit

Qsonica

model 10-180-GI-PI08S

amplification assay

DNase-RNase- free
coupled with a
microplate horn filled
with 700 mL filtered
water
maintain constant 37
°C

